var title_f15_55_16240="Longitudinal melanonychia pseudo Hutchinson";
var content_f15_55_16240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Nail matrix nevus with pseudo-Hutchinson sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16240=[""].join("\n");
var outline_f15_55_16240=null;
var title_f15_55_16241="Nitrendipine: International drug information";
var content_f15_55_16241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitrendipine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4089120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil (ES);",
"     </li>",
"     <li>",
"      Baylotensin (JP);",
"     </li>",
"     <li>",
"      Bayotensin (DE);",
"     </li>",
"     <li>",
"      Baypresol (ES);",
"     </li>",
"     <li>",
"      Baypress (AR, AU, BE, CH, CZ, DK, FR, HU, IT, LU, NL, PL);",
"     </li>",
"     <li>",
"      Deiten (IT);",
"     </li>",
"     <li>",
"      Farnitran (PT);",
"     </li>",
"     <li>",
"      Gericin (ES);",
"     </li>",
"     <li>",
"      Hiperdipina (PT);",
"     </li>",
"     <li>",
"      Jutapress (DE);",
"     </li>",
"     <li>",
"      Lusopress (IT);",
"     </li>",
"     <li>",
"      Monopress (ES);",
"     </li>",
"     <li>",
"      Nidrel (FR);",
"     </li>",
"     <li>",
"      Niprina (ES);",
"     </li>",
"     <li>",
"      Nirapel (AR);",
"     </li>",
"     <li>",
"      Nitre AbZ (DE);",
"     </li>",
"     <li>",
"      Nitre-Puren (DE);",
"     </li>",
"     <li>",
"      Nitregamma (DE);",
"     </li>",
"     <li>",
"      Nitren 1A Pharma (DE);",
"     </li>",
"     <li>",
"      Nitren acis (DE);",
"     </li>",
"     <li>",
"      Nitren Lich (DE);",
"     </li>",
"     <li>",
"      Nitrencord (BR);",
"     </li>",
"     <li>",
"      Nitrendepat (DE);",
"     </li>",
"     <li>",
"      Nitrendi-BASF (DE);",
"     </li>",
"     <li>",
"      Nitrendil (AR);",
"     </li>",
"     <li>",
"      Nitrendimerck (DE);",
"     </li>",
"     <li>",
"      Nitrendipin AL (DE);",
"     </li>",
"     <li>",
"      Nitrendipin Apogepha (DE);",
"     </li>",
"     <li>",
"      Nitrendipin Atid (DE);",
"     </li>",
"     <li>",
"      Nitrendipin Basics (DE);",
"     </li>",
"     <li>",
"      Nitrendipin beta (DE);",
"     </li>",
"     <li>",
"      nitrendipin corax (DE);",
"     </li>",
"     <li>",
"      Nitrendipin Heumann (DE);",
"     </li>",
"     <li>",
"      Nitrendipin Jenapharm (DE);",
"     </li>",
"     <li>",
"      Nitrendipin Lindo (DE);",
"     </li>",
"     <li>",
"      Nitrendipin Stada (DE);",
"     </li>",
"     <li>",
"      nitrendipin von ct (DE);",
"     </li>",
"     <li>",
"      Nitrendipin-ratiopharm (DE);",
"     </li>",
"     <li>",
"      Nitrendipino Bayvit (ES);",
"     </li>",
"     <li>",
"      Nitrendipino Ratiopharm (ES);",
"     </li>",
"     <li>",
"      Nitrendypina (PL);",
"     </li>",
"     <li>",
"      Nitrensal (DE);",
"     </li>",
"     <li>",
"      Nitrepress (DE);",
"     </li>",
"     <li>",
"      Sub Tensin (ES);",
"     </li>",
"     <li>",
"      Tensogradal (ES);",
"     </li>",
"     <li>",
"      Tocrat (AR);",
"     </li>",
"     <li>",
"      Tracil (AR);",
"     </li>",
"     <li>",
"      Trendinol (ES);",
"     </li>",
"     <li>",
"      Unipres (CZ, HR, HU, PL);",
"     </li>",
"     <li>",
"      Vastensium (ES);",
"     </li>",
"     <li>",
"      Veraxin (HR);",
"     </li>",
"     <li>",
"      Xasmun (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4089121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4089123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     20 mg/day (in patients with liver disease or in the elderly, an initial dose of 10 mg is recommended); maximum dose: 40 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10516 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16241=[""].join("\n");
var outline_f15_55_16241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089120\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089121\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089123\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821073\">",
"      Product Availability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10516\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10516|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_55_16242="Leukocytoclastic vasculitis with ulcer";
var content_f15_55_16242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous small vessel vasculitis with ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A small ulcer and areas of hyperpigmentation are present in this patient with cutaneous small vessel vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16242=[""].join("\n");
var outline_f15_55_16242=null;
var title_f15_55_16243="Nummular headache";
var content_f15_55_16243=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nummular headache",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16243/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16243/contributors\">",
"     F Michael Cutrer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16243/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16243/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16243/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16243/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/55/16243/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nummular headache is one of several relatively uncommon headache syndromes that may occur either as a primary headache or as a headache symptomatic of potentially malignant processes. Careful evaluation for underlying causes is important for these uncommon types of headache.",
"   </p>",
"   <p>",
"    This topic will review nummular headache. Other types of uncommon primary headache disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=see_link\">",
"     \"Primary stabbing headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=see_link\">",
"     \"Primary cough headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=see_link\">",
"     \"Primary exertional headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16054?source=see_link\">",
"     \"Primary headache associated with sexual activity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=see_link\">",
"     \"Thunderclap headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5700?source=see_link\">",
"     \"Hypnic headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Also called coin-shaped headache, nummular headache is characterized by small circumscribed areas of continuous pain on the head [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Nummular headaches are generally of mild to moderate intensity and confined to a round or elliptical unchanging area 2 to 6 cm in diameter. The pain is continuous, although in a large minority of cases, spontaneous remissions lasting weeks to months may occur. Superimposed on the continuous pain, lancinating pain may occur that initially lasts seconds but may gradually increase in duration to minutes or hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. During remissions, the affected area may continue to be allodynic, paresthetic, or hyperesthetic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While nummular headache is typically unifocal, a few patients have been reported with focal head pain in two separate areas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. One series of 16 patients with nummular headache found a disproportionately high occurrence of comorbid migraine (56 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nummular headache is not accompanied by nausea, vomiting, light or sound sensitivity, rhinorrhea, lacrimation, conjunctival injection, or focal neurologic symptoms.",
"   </p>",
"   <p>",
"    Nummular headache is uncommon, with an estimated incidence of 6.4 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes primary (idiopathic) stabbing headache, which unlike nummular headache, tends to be multifocal and variable in location. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=see_link\">",
"     \"Primary stabbing headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential also includes headache resulting from cranial bone lesions caused by metastatic cancer, multiple myeloma, Paget disease of bone, or osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/2\">",
"     2",
"    </a>",
"    ]. In one case, a patient had symptoms typical of primary nummular headache that localized to the left posterior parietal region, where a protruding lesion about 1 cm long was identified on head MRI but not on CT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/7\">",
"     7",
"    </a>",
"    ]. The lesion ended in a point with the bone layer preserved, but its precise nature was unknown.",
"   </p>",
"   <p>",
"    Although there is no clear consensus among experts, we suggest obtaining a head CT or MRI to evaluate for both neoplastic and infectious bone lesions in patients with suspected nummular headache. MRI may have a higher sensitivity than CT in this setting, but data are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nummular headache may be neuralgia of a terminal branch of the trigeminal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/1,8\">",
"     1,8",
"    </a>",
"    ], although its pathophysiology is uncertain. In one series of 16 patients with nummular headache, there was a high prevalence of serum markers of autoimmunity and autoimmune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/9\">",
"     9",
"    </a>",
"    ], suggesting a possible relationship between autoimmunity and nummular headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    (900 to 1800 mg daily) has been reported to be transiently effective and may be attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. There is also a case report of successful treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    (25 mg twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/11\">",
"     11",
"    </a>",
"    ]. However, nummular headache often becomes refractory to all standard prophylactic and analgesic therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16243/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Also called coin-shaped headache, nummular headache is characterized by small circumscribed areas of continuous pain on the head, sometimes accompanied by superimposed lancinating pain. Spontaneous remissions lasting weeks to months may occur. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with suspected nummular headache, we suggest obtaining a head CT to evaluate for metastatic and infectious cranial bone lesions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      (900 to 1800 mg daily) may be transiently effective, but nummular headache often becomes refractory to all standard headache therapies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/1\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/2\">",
"      Pareja JA, Caminero AB, Serra J, et al. Numular headache: a coin-shaped cephalgia. Neurology 2002; 58:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/3\">",
"      Pareja JA, Pareja J, Barriga FJ, et al. Nummular headache: a prospective series of 14 new cases. Headache 2004; 44:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/4\">",
"      Guerrero AL, Cortijo E, Herrero-Vel&aacute;zquez S, et al. Nummular headache with and without exacerbations: comparative characteristics in a series of 72 patients. Cephalalgia 2012; 32:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/5\">",
"      Cuadrado ML, Valle B, Fern&aacute;ndez-de-las-Pe&ntilde;as C, et al. Bifocal nummular headache: the first three cases. Cephalalgia 2009; 29:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/6\">",
"      Moon J, Ahmed K, Garza I. Case series of sixteen patients with nummular headache. Cephalalgia 2010; 30:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/7\">",
"      Alvaro LC, Garc&iacute;a JM, Areitio E. Nummular headache: a series with symptomatic and primary cases. Cephalalgia 2009; 29:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/8\">",
"      Evans RW, Pareja JA. Nummular headache. Headache 2005; 45:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/9\">",
"      Chen WH, Chen YT, Lin CS, et al. A high prevalence of autoimmune indices and disorders in primary nummular headache. J Neurol Sci 2012; 320:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/10\">",
"      Trucco M, Mainardi F, Perego G, Zanchin G. Nummular headache: first Italian case and therapeutic proposal. Cephalalgia 2006; 26:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/11\">",
"      Baldacci F, Nuti A, Lucetti C, et al. Nummular headache dramatically responsive to indomethacin. Cephalalgia 2010; 30:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16243/abstract/12\">",
"      Dach F, Speciali J, Eckeli A, et al. Nummular headache: three new cases. Cephalalgia 2006; 26:1234.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3329 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16243=[""].join("\n");
var outline_f15_55_16243=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5700?source=related_link\">",
"      Hypnic headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=related_link\">",
"      Primary cough headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=related_link\">",
"      Primary exertional headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16054?source=related_link\">",
"      Primary headache associated with sexual activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=related_link\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=related_link\">",
"      Thunderclap headache",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_55_16244="Palmar hand anatomy";
var content_f15_55_16244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palmar hand anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The path of palmar arteries (red) and nerves (green) to the fingers is shown. Each digit is innervated by four digital nerves; the dorsal arteries and nerves are not shown in this figure. In order to achieve a complete anesthetic effect, it is necessary to block all four nerves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16244=[""].join("\n");
var outline_f15_55_16244=null;
var title_f15_55_16245="OnabotulinumtoxinA (botulinum toxin type A, Botox): Patient drug information";
var content_f15_55_16245=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   OnabotulinumtoxinA (botulinum toxin type A, Botox): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     see \"OnabotulinumtoxinA (botulinum toxin type A, Botox): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/18/295?source=see_link\">",
"     see \"OnabotulinumtoxinA (botulinum toxin type A, Botox): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Botox&reg;;",
"     </li>",
"     <li>",
"      Botox&reg; Cosmetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Botox&reg;;",
"     </li>",
"     <li>",
"      Botox&reg; Cosmetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad side effects have happened when this drug has spread from where it is being used.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691338",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the number of lines and wrinkles of the face and neck.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower underarm sweating.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691719",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anal fissures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691970",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat muscle problems around the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691971",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat muscle problems that lead to spasms.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692091",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat spasms of the head. It may take 2 weeks to get better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat an overactive bladder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to onabotulinumtoxinA, albumin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703160",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an infection where the shot will be given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703746",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a botulinum toxin product in the last 3 or 4 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble swallowing, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698253",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness or changes in eyesight may happen. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698277",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Neck pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Less blinking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seeing double.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry eyes. Using artificial tears may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eyelid droop.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ulcers may  rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding in the eye may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble swallowing or speaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to control bladder.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the muscle(s) causing the spasms.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into the skin near the parts where there is sweating.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11395 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-40244E071D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16245=[""].join("\n");
var outline_f15_55_16245=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141936\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141937\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022999\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023001\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023000\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023005\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023006\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023008\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023003\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023004\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023010\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=related_link\">",
"      OnabotulinumtoxinA (botulinum toxin type A, Botox): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/18/295?source=related_link\">",
"      OnabotulinumtoxinA (botulinum toxin type A, Botox): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_55_16246="Rabies virus vaccine: Drug information";
var content_f15_55_16246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rabies virus vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/33/10769?source=see_link\">",
"    see \"Rabies virus vaccine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/49/21269?source=see_link\">",
"    see \"Rabies virus vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Imovax&reg; Rabies;",
"     </li>",
"     <li>",
"      RabAvert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Imovax&reg; Rabies;",
"     </li>",
"     <li>",
"      RabAvert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pre-exposure vaccination:",
"     </b>",
"     I.M.: A total of 3 doses, 1 mL each, on days 0, 7, and 21-28.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Prolonging the interval between doses does not interfere with immunity achieved after the concluding dose of the basic series.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postexposure vaccination:",
"     </b>",
"     All postexposure treatment should begin with immediate cleansing of the wound with soap and water",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Persons not previously immunized as above: I.M.: 5 doses (1 mL each) on days 0, 3, 7, 14, 28.  In addition, patients should receive rabies immune globulin with the first dose (day 0).",
"     <b>",
"      Note:",
"     </b>",
"     A regimen of 4 doses (1 mL each) on days 0, 3, 7, 14 may be used in persons who are not immunosuppressed (ACIP recommendations, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Persons who have previously received postexposure prophylaxis with rabies vaccine, received a recommended I.M. pre-exposure series of rabies vaccine or have a previously documented rabies antibody titer considered adequate: I.M.: Two doses (1 mL each) on days 0 and 3; do not administer rabies immune globulin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Booster (for persons with continuous or frequent risk of infection): I.M.: 1 mL based on antibody titers",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F216834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/49/21269?source=see_link\">",
"      see \"Rabies virus vaccine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imovax&reg; Rabies: 2.5 units [contains albumin (human), neomycin (may have trace amounts); HDCV; grown in human diploid cell culture; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RabAvert&reg;: 2.5 units [contains albumin (human), amphotericin B (may have trace amounts), bovine gelatin, chicken egg protein, chlortetracycline (may have trace amounts), neomycin (may have trace amounts); PCEC; grown in chicken fibroblast culture; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F216814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.M. administration only; this rabies vaccine product must not be administered intradermally; in adults and children, administer I.M. injections in the deltoid muscle, not the gluteal; for younger children, use the outer aspect of the thigh. Postexposure prophylaxis should begin with immediate cleansing of wounds with soap and water; if available, a virucidal agent (eg povidone-iodine solution) should be used to irrigate the wounds.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. The use of licensed combination vaccines is generally preferred over separate injections of the equivalent components. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pre-exposure and postexposure vaccination against rabies",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends a primary course of prophylactic immunization (pre-exposure vaccination) for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Persons with continuous risk of infection, including rabies research laboratory and biologics production workers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Persons with frequent risk of infection in areas where rabies is enzootic, including rabies diagnostic laboratory workers, cavers, veterinarians and their staff, and animal control and wildlife workers; persons who frequently handle bats",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Persons with infrequent risk of infection, including veterinarians and animal control staff with terrestrial animals in areas where rabies infection is rare, veterinary students, and travelers visiting areas where rabies is enzootic and immediate access to medical care and biologicals is limited",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     The ACIP recommends the use of postexposure vaccination for a particular person be assessed by the severity and likelihood versus the actual risk of acquiring rabies. Consideration should include the type of exposure, epidemiology of rabies in the area, species of the animal, circumstances of the incident, and the availability of the exposing animal for observation or rabies testing. Postexposure vaccination is used in both previously vaccinated and previously unvaccinated individuals.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Erythema, itching, pain, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Uncommon, frequency not defined, postmarketing, and/or case reports:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Circulatory reactions, edema, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, fatigue, fever &gt;38&deg;C (100&deg;F), Guillain-Barr&eacute; syndrome, encephalitis, meningitis, multiple sclerosis, myelitis, neuroparalysis, seizures, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, urticaria, urticaria pigmentosa",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Hematoma, limb swelling (extensive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, limb pain, monoarthritis, neuropathy, paralysis (transient), paresthesias (transient), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Retrobulbar neuritis, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylaxis, hypersensitivity reactions, serum sickness, swollen lymph nodes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pre-exposure prophylaxis: Hypersensitivity to rabies vaccine or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postexposure prophylaxis: There are no contraindications listed within the FDA-approved manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use. Once postexposure prophylaxis has begun, administration should generally not be interrupted or discontinued due to local or mild adverse events. Continuation of vaccination following severe systemic reactions should consider the persons risk of developing rabies. Report serious reactions to the State Health Department or the manufacturer/distributor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune complex-like reactions: An immune complex reaction is possible 2-21 days following booster doses of HDCV. Symptoms may include arthralgia, arthritis, angioedema, fever, generalized urticaria, malaise, nausea, and vomiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. Withhold nonessential immunosuppressive agents during postexposure prophylaxis; if possible postpone pre-exposure prophylaxis until the immunocompromising condition is resolved. Persons with altered immunocompetence should receive the five-dose postexposure vaccine regimen. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Products may contain albumin and therefore carry a remote risk of transmitting Creutzfeldt-Jakob or other viral diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Imovax&reg; Rabies: Contains neomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; RabAvert&reg;: Contains amphotericin B, bovine gelatin, chicken protein, chlortetracycline, and neomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Rabies: Rabies vaccine should not be used in persons with a confirmed diagnosis of rabies; use after the onset of symptoms may be detrimental. Postexposure vaccination may begin regardless of the length of time from documented or likely exposure, as long as clinical signs of rabies are not present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: May diminish the therapeutic effect of Rabies Vaccine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Pregnancy is not a contraindication to postexposure prophylaxis. Pre-exposure prophylaxis during pregnancy may also be considered if risk of rabies is great.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6802359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6802360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast-feeding mothers may be vaccinated. Inactivated virus vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules (CDC, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5687023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Imovax Rabies Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 units/mL (1): $284.42",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F216808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antibody response to vaccination is not recommended for otherwise healthy persons who complete the pre-exposure or postexposure regimen. Serologic testing to determine if the antibody titer is at an acceptable level is required for the following persons (booster vaccination recommended if titer is below the acceptable level):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Persons with continuous risk of infection: Serologic testing every 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Persons with frequent risk of infection: Serologic testing every 2 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Persons who are immunocompromised: Serologic testing after completion of pre-exposure or postexposure prophylaxis series",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Monitoring of antibody response to vaccination is not recommended for otherwise healthy persons who complete the pre-exposure or postexposure regimen.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F216811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate adaptive immune response: antibody titers of 0.5 units/mL [WHO] or complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test (RFFIT) [ACIP]",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abhayrab (TH);",
"     </li>",
"     <li>",
"      Berrab P (HK);",
"     </li>",
"     <li>",
"      Imovax Rabbia (IT);",
"     </li>",
"     <li>",
"      Imovax Rabia (UY);",
"     </li>",
"     <li>",
"      Imovax Rabies (PL);",
"     </li>",
"     <li>",
"      Lyssavac N Berna (HK, MY, PH);",
"     </li>",
"     <li>",
"      Rabies MIRV Vaccine (NZ);",
"     </li>",
"     <li>",
"      Rabies-Imovax (FI, NO, SE);",
"     </li>",
"     <li>",
"      Rabiesvax (PH);",
"     </li>",
"     <li>",
"      Rabipur (AT, AU, BG, CZ, DE, FR, GB, IE, IN, NL, PH, SE, SG, TH);",
"     </li>",
"     <li>",
"      Speeda (PH, TH);",
"     </li>",
"     <li>",
"      Verorab (BG, CL, CO, CR, DO, GT, HN, MY, PA, PE, SV)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F216799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rabies vaccine is an inactivated virus vaccine which promotes immunity by inducing an active immune response. The production of specific antibodies requires about 7-10 days to develop. Rabies immune globulin or antirabies serum, equine (ARS) is given in conjunction with rabies vaccine to provide immune protection until an antibody response can occur.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F216816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.: Rabies antibody: ~7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: ~30-60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &ge;1 year",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A New Rabies Vaccine,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1998, 40(1029):64-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/55/16246/abstract-text/9653425/pubmed\" id=\"9653425\" target=\"_blank\">",
"        9653425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Human Rabies Prevention - United States, 2008 Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-3):1-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/55/16246/abstract-text/18496505/pubmed\" id=\"18496505\" target=\"_blank\">",
"        18496505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/55/16246/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-2):1-9. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr5902.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr5902.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/55/16246/abstract-text/20300058/pubmed\" id=\"20300058\" target=\"_blank\">",
"        20300058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dreesen DW and Hanlon CA, &ldquo;Current Recommendations for the Prophylaxis and Treatment of Rabies,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 56(5):801-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/55/16246/abstract-text/9829154/pubmed\" id=\"9829154\" target=\"_blank\">",
"        9829154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang J and Plotkin SA, &ldquo;Rabies Risk and Immunoprophylaxis in Children,&rdquo;",
"      <i>",
"       Adv Pediatr Infect Dis",
"      </i>",
"      , 1997, 13:219-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/55/16246/abstract-text/9544314/pubmed\" id=\"9544314\" target=\"_blank\">",
"        9544314",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/55/16246/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/55/16246/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strady A, Lang J, Lienard M, et al, &ldquo;Antibody Persistence Following Pre-exposure Regimens of Cell-Culture Rabies Vaccines: 10-Year Follow-up and Proposal for a New Booster Policy,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1998, 177(5):1290-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/55/16246/abstract-text/9593014/pubmed\" id=\"9593014\" target=\"_blank\">",
"        9593014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9850 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16246=[""].join("\n");
var outline_f15_55_16246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216827\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216828\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216838\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216829\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216834\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216830\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216810\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216796\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216814\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216813\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216836\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216817\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216800\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299976\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216804\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216806\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216820\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6802359\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6802360\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5687023\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216808\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216811\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038796\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216799\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216816\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9850\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9850|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/33/10769?source=related_link\">",
"      Rabies virus vaccine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/49/21269?source=related_link\">",
"      Rabies virus vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_55_16247="Reciprocal creatinine graph mg";
var content_f15_55_16247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Reciprocal creatinine graph mg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16247=[""].join("\n");
var outline_f15_55_16247=null;
var title_f15_55_16248="Clinical features and diagnosis of Bordetella pertussis infection in infants and children";
var content_f15_55_16248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16248/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16248/contributors\">",
"     Sylvia Yeh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16248/contributors\">",
"     ChrisAnna M Mink, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16248/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16248/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16248/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/55/16248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation, including complications, and the diagnosis of pertussis infection in infants and children will be discussed here. The pathogenesis, epidemiology, treatment, and prevention of pertussis in infants and children are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20918?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, treatment, and prevention of pertussis in adolescents and adults also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic clinical features of pertussis are readily recognizable as a prolonged respiratory illness with paroxysmal coughing, often followed by forced inspiratory effort, causing a \"whoop\". However, many children who are infected with",
"    <em>",
"     Bordetella pertussis",
"    </em>",
"    do not have this typical constellation of symptoms. Atypical presentations occur frequently in young infants and in vaccinated individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The atypical features vary depending upon age and length of time since the last vaccination.",
"   </p>",
"   <p>",
"    Despite widespread vaccination, the incidence of pertussis has been rising, particularly among adolescents and young adults (",
"    <a class=\"graphic graphic_figure graphicRef73317 \" href=\"UTD.htm?34/14/35053\">",
"     figure 1",
"    </a>",
"    ). As a result, more young infants are exposed to infection. It is in this young population that significant morbidity and mortality occur (",
"    <a class=\"graphic graphic_figure graphicRef67295 \" href=\"UTD.htm?2/9/2207\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An awareness of the clinical features of pertussis infection among patients of different ages and aggressive efforts to confirm the diagnosis are essential in limiting the impact of pertussis. Early diagnosis is important for disease control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\", section on 'Rationale'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of pertussis varies depending upon the age and vaccination status of the child. Atypical presentations occur in young infants, those who have been previously vaccinated, and older children and adolescents with waning immunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average incubation period after exposure to",
"    <em>",
"     B. pertussis",
"    </em>",
"    is 7 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This is followed by onset of nonspecific symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Classical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical pertussis has been called \"the cough of 100 days\" in China. The clinical illness is divided into three stages: catarrhal, paroxysmal, and convalescent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Catarrhal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catarrhal phase appears similar to the \"common cold\", with mild cough and coryza, and generally lasts one to two weeks. Fever is uncommon, and if present, it is usually low grade. Instead of improving, the cough gradually increases, unlike a typical upper respiratory infection (URI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Paroxysmal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the paroxysmal stage, coughing persists and severity increases, occurring in paroxysmal attacks. The classic cough of pertussis is distinctive. The paroxysm is a long series of coughs, during which the child may develop gagging and cyanosis, and appear to be struggling for breath (",
"    <a class=\"graphic graphic_movie graphicRef80861 \" href=\"UTD.htm?33/32/34304\">",
"     movie 1",
"    </a>",
"    ). Whooping, which is characterized by the noise of the forced inspiratory effort, may be observed following a coughing attack during the paroxysmal phase (",
"    <a class=\"graphic graphic_movie graphicRef57822 \" href=\"UTD.htm?10/7/10352\">",
"     movie 2",
"    </a>",
"    ), but is not always present (",
"    <a class=\"graphic graphic_movie graphicRef55250 \" href=\"UTD.htm?10/22/10592\">",
"     movie 3",
"    </a>",
"    ). Post-tussive emesis occurs frequently. Paroxysms can develop spontaneously or be precipitated by external stimuli.",
"   </p>",
"   <p>",
"    The paroxysmal stage may last for two to six weeks. Paroxysms of coughing increase in frequency during the first one to two weeks, remain at the same intensity for two to three weeks, and decrease gradually thereafter. Complications are most likely during the paroxysmal stage. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Convalescent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finally, the cough begins to subside, and the child enters the convalescent stage. The cough continues to decrease gradually over several weeks to months. Episodic coughing may reappear with subsequent URIs during convalescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Atypical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical presentations of pertussis may occur in infants and in children who have been vaccinated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catarrhal stage is often very short or absent in young infants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/7\">",
"     7",
"    </a>",
"    ]. Early symptoms can include feeding difficulties, tachypnea, and cough. Paroxysms of cough, during which the infant may develop gagging, apnea, cyanosis, and bradycardia, may be the only manifestation. The infant can appear deceptively well between episodes of coughing.",
"   </p>",
"   <p>",
"    Many infants with pertussis do not exhibit a characteristic whoop. In one series of hospitalized patients with unrecognized pertussis, only 9 of 24 infants admitted to the pediatric intensive care unit had a whoop [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/1\">",
"     1",
"    </a>",
"    ]. In another series of 44 infants hospitalized with pertussis, only six had a whoop with coughing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the source of infection for most infants with pertussis is a household contact, the history of someone coughing at home adds support to the diagnosis. In a case-controlled study of 39 infants younger than seven months of age with pertussis, multivariate analysis identified young maternal age and mothers who had had cough for seven days or more as risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/9\">",
"     9",
"    </a>",
"    ]. Similarly, among infants and children hospitalized with initially unrecognized pertussis, 22 of 33 had a family member with laboratory-confirmed pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Vaccinated children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because no vaccines, including pertussis, are 100 percent effective in preventing infection, pertussis may occur in vaccinated children. The clinical presentation and course of pertussis infection are generally less severe in children who have been recently vaccinated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A birth cohort of 15,601 children, who were recruited for a trial on acellular pertussis vaccines in Italy, were actively monitored for evidence of pertussis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/11\">",
"     11",
"    </a>",
"    ]. A total of 788 cases of laboratory-confirmed pertussis were diagnosed. Clinical features of pertussis infection in children who had not been vaccinated for pertussis were compared with those who had received one of two different acellular pertussis vaccines. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children in the two groups who received acellular pertussis vaccines had a shorter median duration of cough than those who were unvaccinated during the three stages of the study (29 and 33 days versus 61 days at 6 to 24 months of age; 39 and 31 days versus 60 days at 25 to 33 months; and 35 days [for both groups] versus 52 days at 34 to 72 months)",
"     </li>",
"     <li>",
"      The incidence of apnea among children 6 to 24 months was decreased in the two groups who received acellular pertussis vaccine compared with the unvaccinated group (47 and 36 percent in the vaccinated groups versus 85 percent in the unvaccinated group)",
"     </li>",
"     <li>",
"      The incidence of cyanosis among children 6 to 24 months was decreased in the two groups who received acellular pertussis vaccine compared with the unvaccinated group (31 percent and 21 percent in the vaccinated groups versus 65 percent in the unvaccinated group)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because the presentation of pertussis generally is milder in vaccinated children, a clinical case definition that requires two weeks of cough has the potential to miss less severe cases in vaccinated children. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Clinical diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Older children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither natural infection nor vaccination confers life-long protection. Vaccine-induced immunity wanes, following whole-cell and acellular vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/12\">",
"     12",
"    </a>",
"    ], although the duration of immunity following acellular vaccines is not yet completely defined [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/13\">",
"     13",
"    </a>",
"    ]. Some data demonstrate that immunity following five doses of acellular pertussis vaccine persists for approximately five years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=see_link&amp;anchor=H9#H9\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Efficacy and effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the waning immunity, the presentation of pertussis in vaccinated and unvaccinated older children and adolescents is similar; it is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the white blood cell (WBC) count and differential may be normal, the predominant nonspecific laboratory indication of",
"    <em>",
"     B. pertussis",
"    </em>",
"    infection is an overall leukocytosis resulting from lymphocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The absolute lymphocyte count is often &ge;10,000 lymphocytes per microL. Marked leukocytosis (eg, &gt;60,000",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    has been associated with increased pertussis severity, (including pertussis pneumonia and pulmonary hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/18-22\">",
"     18-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In uncomplicated pertussis, chest radiographs may be normal or demonstrate subtle abnormalities, such as peribronchial cuffing, perihilar infiltrates, or atelectasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications of pertussis infection include apnea, pneumonia, and weight loss secondary to feeding difficulties and post-tussive vomiting. Seizures and death also occur. These complications develop most often among young infants. Other complications include difficulty sleeping, pneumothorax, epistaxis, subconjunctival hemorrhage, subdural hematoma, rectal prolapse, urinary incontinence, and rib fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large multicenter surveillance study, 12 percent of children with prolonged cough had culture-confirmed pertussis; among children with pertussis, the overall complication rate was 6 percent, but among infants younger than six months, the complication rate was 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/26\">",
"     26",
"    </a>",
"    ]. In a retrospective cohort from a single institution, complications occurred in 37 percent of infants younger than six months who were hospitalized with pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/27\">",
"     27",
"    </a>",
"    ]. Age &lt;60 days, cough duration &lt;7 days, history of color change, parenteral intervention for apnea, and the need for oxygen in the emergency department were associated with increased risk of complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apnea occurs almost exclusively in infants, and primarily in those younger than six months of age. It usually is associated with a paroxysm of coughing, but also occurs spontaneously, perhaps related to vagal stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In a large multicenter surveillance study, apnea or cyanosis occurred in 16 percent of infants younger than six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/26\">",
"     26",
"    </a>",
"    ]. In another study, apnea occurred in 31 percent of children younger than two years who were hospitalized for pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia is one of the most frequent complications of pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/26,30-32\">",
"     26,30-32",
"    </a>",
"    ]. Pneumonia may be a primary manifestation of",
"    <em>",
"     B. pertussis",
"    </em>",
"    infection or the result of secondary bacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary pertussis pneumonia is associated with extreme leukocytosis (eg, &gt;60,000",
"    <span class=\"nowrap\">",
"     cells/microL),",
"    </span>",
"    pulmonary hypertension, and increased mortality, particularly in young infants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Death'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vomiting occurs in approximately one-half of children younger than 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/26,30\">",
"     26,30",
"    </a>",
"    ] but may occur in any age group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of new seizures occurred in 1 to 2 percent of the pertussis cases reported to the Centers for Disease Control and Prevention (CDC) in children younger than six months of age between 1997 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], and in 2 percent of the children younger than two years of age hospitalized for pertussis in Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/30\">",
"     30",
"    </a>",
"    ]. The incidence of encephalopathy (pathogenesis not known, but presumably secondary to hypoxia) was 0.4 percent in both populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most deaths from pertussis occur in infants younger than six months of age, who are too young to have completed the primary series of pertussis vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ]. The case fatality rate for pertussis among infants younger than six months of age is approximately 1 percent, with the majority of deaths occurring in those younger than two months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/8,30,32\">",
"     8,30,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case-control study designed to identify predictors of death in cases of fatal pertussis, 15 of 16 fatalities occurred in infants &le;2 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/8\">",
"     8",
"    </a>",
"    ]. Infants intubated for pneumonia were more likely to die than those intubated for apnea. Leukocytosis and pneumonia on initial presentation were predictors of poor outcome.",
"   </p>",
"   <p>",
"    An association between epidemic pertussis and sudden infant death syndrome (SIDS) has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/34\">",
"     34",
"    </a>",
"    ]. However, in a multicenter, case-control study to investigate the relationship between pertussis infection and SIDS, pertussis polymerase chain reaction (PCR) was positive in 5.1 percent of cases and in 5.3 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/35\">",
"     35",
"    </a>",
"    ]. Nonetheless, it is plausible that fatal apnea occurring in an infant with undiagnosed pertussis could present as SIDS. Laboratory testing for pertussis should be considered in cases of apparent SIDS, particularly if the infant or other family members had been coughing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <em>",
"     B. pertussis",
"    </em>",
"    pneumonia is associated with acute pulmonary vasoconstriction and extreme leukocytosis, which ultimately compromise pulmonary blood flow, exacerbate hypoxemia, and create a vicious cycle of refractory pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/18,36\">",
"     18,36",
"    </a>",
"    ]. The pathologic findings of fatal",
"    <em>",
"     B. pertussis",
"    </em>",
"    infection in infants were evaluated in an autopsy study of 15 infants &le;4 months of age who had PCR- or culture-confirmed",
"    <em>",
"     B. pertussis",
"    </em>",
"    pneumonia; 12 of the infants had evidence of pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/18\">",
"     18",
"    </a>",
"    ]. Histopathologic examination of respiratory tissue revealed evidence of necrotizing bronchiolitis, intraalveolar hemorrhage, and fibrinous edema. There were abundant leukocytes and extracellular Bordetellae in the cilia of the respiratory tract, and intracellular bacteria and antigens in alveolar macrophages and ciliated epithelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pertussis is a clinical diagnosis. When the classic features of illness are present, the diagnosis may be readily considered and prompt treatment initiated. Because the spectrum of illness is varied, and the presentation can be atypical, a high index of suspicion must be maintained to make the diagnosis, particularly in infants and previously vaccinated individuals. The diagnosis should be considered in all children, regardless of vaccination status, who present with &ge;14 days of cough [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic testing is important to confirm an uncertain diagnosis and for public health considerations. When a case of pertussis is identified, exposed individuals must be notified and offered preventive measures, if warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A case definition for confirmed and probable cases of pertussis has been established by the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) in conjunction with the Council of State and Territorial Epidemiologists (",
"    <a class=\"graphic graphic_table graphicRef80177 \" href=\"UTD.htm?41/54/42859\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. In the United States, both probable and confirmed cases should be reported to public health authorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For endemic or sporadic cases, a clinical case of pertussis is defined as an acute cough illness lasting at least 14 days accompanied by one of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Paroxysms of coughing",
"     </li>",
"     <li>",
"      Inspiratory whoop",
"     </li>",
"     <li>",
"      Post-tussive vomiting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an outbreak or following household contact to a known case, a clinical case is defined as a cough illness for at least 14 days; presence of the typical pertussis-associated features is not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Laboratory diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although whooping cough is a clinical diagnosis, there are several microbiologic studies available to aid in confirming the diagnosis. These include bacterial culture, polymerase chain reaction (PCR), and serology (",
"    <a class=\"graphic graphic_table graphicRef78189 \" href=\"UTD.htm?2/44/2765\">",
"     table 2",
"    </a>",
"    ). Among these, only culture and PCR meet criteria for laboratory confirmation of a case for national reporting purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/40\">",
"     40",
"    </a>",
"    ]. However, epidemic investigations have revealed that PCR may be associated with false-positive results and should not be the only laboratory test to confirm clinical pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Direct fluorescent antibody (DFA) suffers from variable sensitivity and specificity and should not routinely be used.",
"   </p>",
"   <p>",
"    It is important to perform laboratory testing as soon as the diagnosis of pertussis is considered. The",
"    <em>",
"     B. pertussis",
"    </em>",
"    organism is more difficult to grow from specimens obtained during or after the paroxysmal phase, and after antibiotic therapy has been initiated.",
"   </p>",
"   <p>",
"    The individual laboratory tests and the recommended approach according to the time after symptom onset are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other",
"    <em>",
"     Bordetella",
"    </em>",
"    species, such as",
"    <em>",
"     B. parapertussis",
"    </em>",
"    ,",
"    <em>",
"     B. bronchiseptica",
"    </em>",
"    , and",
"    <em>",
"     B. holmesii",
"    </em>",
"    may cause paroxysmal cough similar to whooping cough [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/16,43-45\">",
"     16,43-45",
"    </a>",
"    ]. These agents can be challenging for the laboratory to isolate and differentiate from",
"    <em>",
"     B. pertussis",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    <em>",
"     Mycoplasma pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     Chlamydia",
"    </em>",
"    spp, tuberculosis, and viral pathogens (respiratory syncytial virus [RSV], adenovirus, parainfluenza [viruses], influenza A and B [viruses], and rhinovirus) can cause illnesses with intractable coughing (see appropriate topic reviews). In addition, these infections may occur in conjunction with pertussis. In a study of hospitalized infants with pertussis, 11 of 33 (33 percent) infants with culture-confirmed",
"    <em>",
"     B. pertussis",
"    </em>",
"    infection had coinfection with RSV [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16248/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, the identification of a viral agent does not exclude the diagnosis of pertussis.",
"   </p>",
"   <p>",
"    Noninfectious processes to consider include foreign body aspiration, reactive airway",
"    <span class=\"nowrap\">",
"     disease/asthma,",
"    </span>",
"    allergic or infectious sinusitis, gastroesophageal reflux, and aspiration pneumonia. These conditions are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=see_link\">",
"       \"Patient information: Whooping cough (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=see_link\">",
"       \"Patient information: Cough in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pertussis infection frequently is unrecognized, even in patients with paroxysmal cough or with cough for a prolonged duration. Atypical presentations in infants, older children, and adults and previously vaccinated individuals also contribute to underdiagnosis. Early diagnosis is important for disease control. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link\">",
"       \"Treatment and prevention of Bordetella pertussis infection in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pertussis should be suspected in the following patients (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infants and children with paroxysmal cough (",
"      <a class=\"graphic graphic_movie graphicRef80861 \" href=\"UTD.htm?33/32/34304\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef57822 \" href=\"UTD.htm?10/7/10352\">",
"       movie 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef55250 \" href=\"UTD.htm?10/22/10592\">",
"       movie 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infants and children who have had a severe cough for more than five to seven days",
"     </li>",
"     <li>",
"      Infants who develop apnea, cyanosis, or gagging with cough",
"     </li>",
"     <li>",
"      Infants with persistent cough and post-tussive emesis, or who have poor weight gain",
"     </li>",
"     <li>",
"      Older children, adolescents, and adults with persistent cough for more than seven days (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the diagnosis of pertussis is suspected, laboratory testing is recommended, and the child must begin antimicrobial therapy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Laboratory diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=see_link\">",
"       \"Treatment and prevention of Bordetella pertussis infection in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Confirmed cases of pertussis should be reported to public health authorities. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/1\">",
"      Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child 2003; 88:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/2\">",
"      Hoppe JE. Neonatal pertussis. Pediatr Infect Dis J 2000; 19:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/3\">",
"      Edwards KM, Halasa N. Are pertussis fatalities in infants on the rise? What can be done to prevent them? J Pediatr 2003; 143:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/4\">",
"      Kowalzik F, Barbosa AP, Fernandes VR, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 2007; 26:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/5\">",
"      Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis 1999; 28 Suppl 2:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/6\">",
"      GORDON JE, HOOD RI. Whooping cough and its epidemiological anomalies. Am J Med Sci 1951; 222:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/7\">",
"      Nieves DJ, Singh J, Ashouri N, et al. Clinical and laboratory features of pertussis in infants at the onset of a California epidemic. J Pediatr 2011; 159:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/8\">",
"      Mikelova LK, Halperin SA, Scheifele D, et al. Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr 2003; 143:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/9\">",
"      Izurieta HS, Kenyon TA, Strebel PM, et al. Risk factors for pertussis in young infants during an outbreak in Chicago in 1993. Clin Infect Dis 1996; 22:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/10\">",
"      Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children. Pediatr Infect Dis J 1995; 14:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/11\">",
"      Tozzi AE, Rav&agrave; L, Ciofi degli Atti ML, et al. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. Pediatrics 2003; 112:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/12\">",
"      Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/13\">",
"      Mink CA, Sirota NM, Nugent S. Outbreak of pertussis in a fully immunized adolescent and adult population. Arch Pediatr Adolesc Med 1994; 148:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/14\">",
"      Heininger U, DTP-HBV-IPV-059 Study Group, DTP-HBV-IPV-096 Study Group, et al. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007; 25:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/15\">",
"      Barreto L, Guasparini R, Meekison W, et al. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 2007; 25:8172.",
"     </a>",
"    </li>",
"    <li>",
"     Cherry JD, Heininger U. Pertussis and other Bordetella infections. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.1683.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/17\">",
"      Levene I, Wacogne I. Question 3. Is measurement of the lymphocyte count useful in the investigation of suspected pertussis in infants? Arch Dis Child 2011; 96:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/18\">",
"      Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008; 47:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/19\">",
"      Seitz RP. Extreme leukocytosis in pertussis: a survey of the literature and report of two cases. Am J Dis Child 1925; 30:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/20\">",
"      Donoso A, Le&oacute;n J, Ram&iacute;rez M, et al. Pertussis and fatal pulmonary hypertension: a discouraged entity. Scand J Infect Dis 2005; 37:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/21\">",
"      Halasa NB, Barr FE, Johnson JE, Edwards KM. Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? Pediatrics 2003; 112:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/22\">",
"      Pierce C, Klein N, Peters M. Is leukocytosis a predictor of mortality in severe pertussis infection? Intensive Care Med 2000; 26:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/23\">",
"      Tiwari T, Murphy TV, Moran J, National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/24\">",
"      Mark A, Granstr&ouml;m M. Impact of pertussis on the afflicted child and family. Pediatr Infect Dis J 1992; 11:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/25\">",
"      Postels-Multani S, Schmitt HJ, Wirsing von K&ouml;nig CH, et al. Symptoms and complications of pertussis in adults. Infection 1995; 23:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/26\">",
"      Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics 1997; 100:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/27\">",
"      Wallace SS, Cruz AT, Quinonez RA, Caviness AC. Risk factors for complications in hospitalized young infants presenting with uncomplicated pertussis. Hosp Pediatr 2011; 1:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/28\">",
"      Vincent JM, Wack RP, Person DA, Bass JW. Pertussis as the cause of recurrent bradycardia in a young infant. Pediatr Infect Dis J 1991; 10:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/29\">",
"      Surridge J, Segedin ER, Grant CC. Pertussis requiring intensive care. Arch Dis Child 2007; 92:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/30\">",
"      Halperin SA, Wang EE, Law B, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT). Clin Infect Dis 1999; 28:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Pertussis--United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/32\">",
"      Centers for Disease Control and Prevention (CDC). Pertussis--United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2005; 54:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/33\">",
"      Haberling DL, Holman RC, Paddock CD, Murphy TV. Infant and maternal risk factors for pertussis-related infant mortality in the United States, 1999 to 2004. Pediatr Infect Dis J 2009; 28:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/34\">",
"      Lindgren C, Milerad J, Lagercrantz H. Sudden infant death and prevalence of whooping cough in the Swedish and Norwegian communities. Eur J Pediatr 1997; 156:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/35\">",
"      Heininger U, Kleemann WJ, Cherry JD, Sudden Infant Death Syndrome Study Group. A controlled study of the relationship between Bordetella pertussis infections and sudden unexpected deaths among German infants. Pediatrics 2004; 114:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/36\">",
"      Sawal M, Cohen M, Irazuzta JE, et al. Fulminant pertussis: a multi-center study with new insights into the clinico-pathological mechanisms. Pediatr Pulmonol 2009; 44:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/37\">",
"      Harnden A, Grant C, Harrison T, et al. Whooping cough in school age children with persistent cough: prospective cohort study in primary care. BMJ 2006; 333:174.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Pertussis surveillance: a global meeting, Geneva 2000. www.who.int/vaccines-documents/DocsPDF01/www605.pdf (Accessed on November 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/39\">",
"      Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     Council on State and Territorial Epidemiolologists (CSTE). 1997 Position Statements. CSTE National Meeting, Saratoga Springs, NY:CSTE. Position statement 9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/41\">",
"      Centers for Disease Control and Prevention (CDC). Outbreaks of respiratory illness mistakenly attributed to pertussis--New Hampshire, Massachusetts, and Tennessee, 2004-2006. MMWR Morb Mortal Wkly Rep 2007; 56:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/42\">",
"      Mandal S, Tatti KM, Woods-Stout D, et al. Pertussis Pseudo-outbreak linked to specimens contaminated by Bordetella pertussis DNA From clinic surfaces. Pediatrics 2012; 129:e424.",
"     </a>",
"    </li>",
"    <li>",
"     Waters V, Halperin S. Bordetella pertussis. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th, Mandell GL, Bennett JE, Dolin R (Eds), Elsevier, Churchill, Livingstone, Philadelphia 2009. p.2955.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/44\">",
"      Rodgers L, Martin SW, Cohn A, et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis--Ohio, 2010-2011. Clin Infect Dis 2013; 56:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16248/abstract/45\">",
"      Kamiya H, Otsuka N, Ando Y, et al. Transmission of Bordetella holmesii during pertussis outbreak, Japan. Emerg Infect Dis 2012; 18:1166.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5995 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16248=[""].join("\n");
var outline_f15_55_16248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Classical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Catarrhal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Paroxysmal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Convalescent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Atypical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Vaccinated children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Older children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Apnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Vomiting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Laboratory diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5995\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5995|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/14/35053\" title=\"figure 1\">",
"      Incidence pertussis US 1990 to 2011",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/9/2207\" title=\"figure 2\">",
"      Pertussis by age group US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5995|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?33/32/34304\" title=\"movie 1\">",
"      Pertussis infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?10/7/10352\" title=\"movie 2\">",
"      Classical whooping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?10/22/10592\" title=\"movie 3\">",
"      Whooping cough no whoop",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5995|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/54/42859\" title=\"table 1\">",
"      Pertussis CDC case definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/44/2765\" title=\"table 2\">",
"      Lab tests for pertussis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=related_link\">",
"      Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20918?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=related_link\">",
"      Patient information: Cough in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=related_link\">",
"      Patient information: Whooping cough (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25833?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_55_16249="Treatment of vulvodynia";
var content_f15_55_16249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of vulvodynia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16249/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16249/contributors\">",
"     Elizabeth Gunther Stewart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16249/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16249/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16249/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/55/16249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar pain can impact quality of life through detrimental effects on daily comfort and sexual function. Approximately 15 percent of women have experienced vulvar pain lasting three or more months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few high quality data regarding the management of vulvodynia. Treatment is based upon the few randomized trials, but largely upon findings of small observational studies, case reports, and clinical experience. Studies with long-term follow-up are lacking. In addition, few interventions have been compared with placebo. Such research is needed, since treatment of vulvodynia has the potential for a large placebo effect, similar to other chronic pain conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successful therapy often requires trial and more than one type of therapeutic intervention may be needed. The process of finding an effective treatment is often time-consuming and frustrating to patients and clinicians. A multidisciplinary team approach is useful and should address the psychology of pain, sexual issues, involvement of the pelvic floor, and the possibility that multiple sources of pain may be present in some women.",
"   </p>",
"   <p>",
"    The management of women with vulvodynia will be reviewed here. Clinical manifestations and diagnosis of the two main types of vulvodynia, as well as of vulvar pain related to a specific disorder, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/46/37609?source=see_link\">",
"     \"Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8295?source=see_link\">",
"     \"Clinical manifestations and diagnosis of generalized vulvodynia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43032?source=see_link\">",
"     \"Approach to the woman with sexual pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=see_link\">",
"     \"Vulvar lichen sclerosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link\">",
"     \"Vulvar lichen planus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4070616\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terminology used to describe vulvar pain syndromes has varied over time. The current classification system, which was agreed upon at the 2003 Congress of the International Society for the Study of Vulvovaginal Disease, consists of two major categories [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vulvar pain related to a specific disorder",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infectious (eg, candidiasis, trichomoniasis, herpes simplex virus)",
"     </li>",
"     <li>",
"      Inflammatory (eg, lichen simplex chronicus, lichen sclerosus, lichen planus, atrophic vaginitis, immunobullous disorder)",
"     </li>",
"     <li>",
"      Neoplastic (eg, Paget disease, squamous cell carcinoma)",
"     </li>",
"     <li>",
"      Neurologic (",
"      <a class=\"graphic graphic_table graphicRef65491 \" href=\"UTD.htm?7/2/7211\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vulvodynia",
"      </strong>",
"      - Vulvar discomfort, most often described as burning pain, occurring in the absence of relevant visible findings or a specific, clinically identifiable, neurologic disorder. The term vestibulitis has been eliminated from this terminology because the presence of inflammation (implied by the suffix &ldquo;-it is&rdquo;) has not be documented. Vulvodynia is divided into two subcategories:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Generalized",
"      </strong>",
"      &ndash; Generalized vulvar discomfort that is provoked (by physical contact that is sexual, nonsexual, or both); unprovoked; or mixed (a combination of provoked and unprovoked).",
"     </li>",
"     <li>",
"      <strong>",
"       Localized",
"      </strong>",
"      (eg, vestibulodynia, clitorodynia, hemivulvodynia) &ndash; Localized vulvar pain that is provoked (by physical contact that is sexual, nonsexual, or both); unprovoked; or mixed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4070835\">",
"    <span class=\"h2\">",
"     Diagnosis and evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to pain of the vulvar vestibule or other vulvar sites is a thorough evaluation to determine if an etiology can be identified. Women may either have vulvar pain related to a specific disorder or idiopathic pain, referred to as vulvodynia. Evaluation of women with vulvar pain is discussed separately. (See",
"    <a class=\"local\" href=\"#H4070616\">",
"     'Terminology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43032?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to the woman with sexual pain\", section on 'Diagnosis and evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/46/37609?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)\", section on 'Diagnosis and evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8295?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of generalized vulvodynia\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with vulvar pain related to a specific disorder require treatment of pain, as well as treatment of the underlying disorder. Examples of this include antifungal medication for prevention of recurrent vulvovaginal candidiasis, treatment of lichen sclerosus or lichen planus, suspension of potential offending contactants or foods, or use of condoms to avoid allergens in semen. Desquamative inflammatory vaginitis is often the cause of persistent vestibular pain. Evaluation of wet mount by microscopy is essential at every visit to look for presence of increased white blood cells, presence of parabasal cells and loss of lactobacilli to make this diagnosis. (See",
"    <a class=\"local\" href=\"#H4071161\">",
"     'Vulvar care'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Diet'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=see_link&amp;anchor=H12#H12\">",
"     \"Vulvar lichen sclerosus\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link&amp;anchor=H10#H10\">",
"     \"Vulvar lichen planus\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2392?source=see_link\">",
"     \"Allergic reactions to seminal plasma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37876?source=see_link\">",
"     \"Desquamative inflammatory vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approaches to management of women with vulvodynia include: education about the condition, behavior modification, emotional support, vulvar care measures, and pharmacologic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should educate the woman that the cause and natural history of vulvodynia are unknown. It is also important to counsel the woman that management of pain may require trying a series of treatment or combinations of treatment, since no single treatment is effective in all women. A therapeutic effect may not be seen for weeks to months and complete resolution of pain may not occur.",
"   </p>",
"   <p>",
"    Informational handouts are an important part of a comprehensive treatment approach. Patients may find information and group support from the National Vulvodynia Association (",
"    <a class=\"external\" href=\"file://www.nva.org/\">",
"     www.nva.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4071161\">",
"    <span class=\"h2\">",
"     Vulvar care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to vulvar care is essential for women with vulvar pain (",
"    <a class=\"graphic graphic_table graphicRef64538 \" href=\"UTD.htm?35/49/36635\">",
"     table 2",
"    </a>",
"    ). The following activities should be avoided because of potentially adverse effects on the vulva:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of scented products, dyes, chemicals, or contactants directly on the vulva or on clothing that touches the vulva",
"     </li>",
"     <li>",
"      Tight, synthetic, or uncomfortable clothing",
"     </li>",
"     <li>",
"      Abrasive activities, such as biking or horseback riding",
"     </li>",
"     <li>",
"      Daily use of mini-pads",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hydration through 5- to 10-minute sitz baths in comfortable warm water two times daily followed by application of a thin film of petroleum jelly to seal in the moisture is a mainstay of any vulvar care regimen. However, women should avoid prolonged, hot soaks.",
"   </p>",
"   <p>",
"    Application of cold to the vulva can provide significant relief from burning in the vestibule or from postcoital soreness. Prolonged application should be avoided to prevent frostbite. A gel pack cooled in the refrigerator, wrapped in a soft cloth, and changed frequently is the best option. Alternatively, crushed ice in a plastic bag or a condom with the end tied shut or small packages of frozen food (eg, peas, corn) and wrapped in a soft cloth mold nicely to vulvar anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sexual and psychological issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual and psychological issues (sexual dysfunction, anxiety, depression, addiction) often arise as a result of chronic vulvar pain and dyspareunia and need to be addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/5\">",
"     5",
"    </a>",
"    ]. Couples therapy and sexual therapy are valuable, but may not be practical until the pain is controlled. Psychosexual therapy can be combined with physical and other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We ask women who have pain on penetration to desist from vaginal intercourse until there has been some improvement in symptoms. Ongoing intercourse in the presence of pain is a negative reinforcer and can lead to secondary vaginismus. We encourage open communication between partners and consideration of pursuing alternatives to vaginal intercourse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23128?source=see_link&amp;anchor=H7#H7\">",
"     \"Differential diagnosis of sexual pain in women\", section on 'Vaginismus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If sexual intercourse is possible with a level of comfort acceptable to the woman, we recommend use of a lubricant. Since many women react to preservatives in commercial products, a few drops of plain baby oil without fragrance may be well-tolerated as long as condoms are not being used. Latex condoms are not compatible with oil-based lubricants or medications. In women using condoms, a water-based lubricant is appropriate (eg, an iso-osmotic, pH balanced product, eg, Pre-Seed&reg;). Some women find a decrease in sexual pain with use of certain sexual positions. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be value in a trial of eliminating known bladder irritants in women who report urinary symptoms as part of their pain. These include foods high in acidity (tomatoes, alcohol, foods with citric acid), chocolate, caffeine, artificial sweeteners, and spices [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link\">",
"     \"Management of interstitial cystitis/bladder pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dietary oxalate consumption does",
"    <strong>",
"     not",
"    </strong>",
"    appear to be associated with an elevated risk of vulvar pain syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/8\">",
"     8",
"    </a>",
"    ]. We avoid evaluation and treatment of hyperoxaluria in women with vulvar pain due to its low yield and economic burden [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4071285\">",
"    <span class=\"h2\">",
"     Role of oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest an association between use of estrogen-progestin oral contraceptives and localized vulvodynia. One study found that oral contraceptives caused vulvar atrophy and decreased pain thresholds [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/10\">",
"     10",
"    </a>",
"    ]. Discontinuation of oral contraceptives and applying a compounded topical estradiol 0.03 percent with testosterone 0.1 percent has been reported to be effective for localized vulvodynia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/11\">",
"     11",
"    </a>",
"    ]. It has been our experience that discontinuing oral contraceptives for women who have taken them for more than five continuous years and using the",
"    <span class=\"nowrap\">",
"     estradiol/testosterone",
"    </span>",
"    treatment for 12 weeks or longer may improve localized pain. Alternatively, topical estrogen could be used, as well (without testosterone).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4071325\">",
"    <span class=\"h2\">",
"     Multidisciplinary approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with vulvodynia may be managed by a primary care clinician or gynecologist. If pain persists despite general measures, women should be evaluated by a gynecologist and referrals to other specialists may be appropriate.",
"   </p>",
"   <p>",
"    Combined treatment approaches for vulvodynia may be more useful than a single approach [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/12\">",
"     12",
"    </a>",
"    ]. Further evaluation or therapy may be provided by the following clinicians: pain specialist, pelvic physical therapist, psychotherapist, sex therapist. Women with orthopedic, neurologic, dermatologic, or urologic findings that potentially contribute to pain should be evaluated as appropriate. Referral to specialists with experience with vulvodynia is preferred, if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PELVIC FLOOR MUSCLE REHABILITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We refer the majority of our patients with localized provoked pain for physical therapy to the pelvic floor with biofeedback.",
"   </p>",
"   <p>",
"    Pelvic floor physical therapy is useful for women with sexual pain and evidence of pelvic floor muscle hypertonicity. Physical therapy is most useful in women with vulvar pain who also have vaginismus, back pain, or muscle spasm. High muscle tone or spasm and instability within the pelvic floor musculature can be identified and relieved with specific exercises. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5305?source=see_link\">",
"     \"Treatment of myofascial pelvic pain syndrome in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pelvic floor physical therapy consists of internal and external soft tissue mobilization, internal and external therapeutic exercise, and pelvic floor retraining with biofeedback. This may decrease introital tenderness and enable resumption of sexual intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. The physical therapist should have experience in treating women with vulvar pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Avoidance of constipation is important to the health of the pelvic floor musculature. Addition of fiber to the diet, as well as use of a fiber supplement according to package instructions, is recommended to women with chronic constipation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of medications has been used for treatment of vulvodynia, but no single agent has been shown to be effective in the majority of women. Thus, a trial of several different medications is typically necessary.",
"   </p>",
"   <p>",
"    Until more evidence is available, our approach is to exclude specific conditions, such as a dermatosis. We use single agent therapy and choose a medication that has a low risk of side effects, typically a topical anesthetic or topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    6 percent combined with physical therapy to the pelvic floor for women with provoked localized vulvar pain, and a tricyclic antidepressant with or without a topical anesthetic for women with unprovoked vulvar pain.",
"   </p>",
"   <p>",
"    A minimum of three months should be allowed before expecting any therapeutic effects. Using combinations of drugs may be effective when treatment with several single agents has failed, but must be done cautiously, given potential side effects.",
"   </p>",
"   <p>",
"    General principles of treatment of chronic pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Topical anesthetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    is an important adjunct in managing pain, in our experience.",
"   </p>",
"   <p>",
"    Topical anesthetics may be applied up to six times per day to provide temporary and partial relief of vulvar pain. We suggest an ointment or a cream compounded in a neutral base since gels and commercial creams can irritate the vestibular epithelium. In our practice, we use topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    5 percent compounded in a neutral base.&nbsp;",
"   </p>",
"   <p>",
"    Topical anesthetics may cause stinging or sensitization. Male partners may experience penile numbness and should avoid oral contact.",
"   </p>",
"   <p>",
"    Topical anesthetics can be applied to the vestibule, as needed, to permit vaginal intercourse in women with minor pain on penetration (ie, 1 to 2 on a scale of 1 to 10). One teaspoon of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    5 percent ointment is applied to the vestibule 20 to 30 minutes prior to intercourse. Avoiding the clitoral area is important. Any excess is wiped away just prior to sexual activity to minimize oral or penile numbness.",
"   </p>",
"   <p>",
"    Consistent use of topical anesthetics for several weeks may provide extended partial pain relief. A randomized trial that evaluated treatments for vestibulodynia compared topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    5 percent applied to the vestibule four times per day for 16 weeks to electromyographic biofeedback [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/20\">",
"     20",
"    </a>",
"    ]. Both treatments resulted in significant improvement in pain, sexual function, and psychosocial adjustment at 12-months follow-up. There were no differences in outcome between the two treatments, but the trial was underpowered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricyclic antidepressants are effective drugs for treatment of neuropathic pain and are frequently prescribed for vulvodynia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/21\">",
"     21",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     Desipramine",
"    </a>",
"    has been helpful for localized provoked pain, but was no better than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or placebo in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/22\">",
"     22",
"    </a>",
"    ]. Up to 47 percent complete response rate is reported for unprovoked pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    are less sedating than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and have fewer anticholinergic side effects (dry mouth, constipation, sweating, palpitations). An electrocardiogram should be obtained in women over 50 years of age and should be normal prior to initiating therapy. If it is abnormal, or it is in women with a history of a cardiac arrhythmia, we suggest consultation with the patient's primary care provider or a cardiologist.",
"   </p>",
"   <p>",
"    We begin treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    10 mg at bedtime and increase the dose by 10 mg every five days to 50 mg at bedtime. If the patient is extremely sensitive to medications, nortriptyline syrup (10",
"    <span class=\"nowrap\">",
"     mg/tsp)",
"    </span>",
"    can be used to help acclimate the patient to the drug side effects through gradual increase from doses under 10 mg. If the patient is tolerating the side effects, the dose should be slowly increased to a total maximum dose of 100 to 150 mg per day. Common reasons for treatment failure are inadequate dosage or a short duration of therapy since it takes weeks to observe an effect. Nortriptyline or desipramine 100 to 150 mg for three months without improvement would prompt us to move to another agent. If one tricyclic antidepressant is not helpful, other members of the tricyclic family may be tried (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ). Within this class of drugs, secondary amines (eg, nortriptyline, desipramine) have fewer side effects than tertiary amines (eg, amitriptyline, imipramine), but appear to be equally effective for treatment of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link&amp;anchor=H5#H5\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\", section on 'Prescribing cyclic antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathic pain can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    (100 mg at bedtime, increasing by 100 mg every two to seven days to 3600 mg in divided doses three times per day, depending on patient tolerance). In one study of 152 women with vulvar pain treated with gabapentin, 98 (64 percent) achieved resolution of at least 80 percent of their symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/24\">",
"     24",
"    </a>",
"    ]. A topical preparation is not commercially available, but has been compounded by a compounding pharmacy as a 2, 4, or 6 percent cream, and appeared to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    is popular for its low side effect profile, as it does not have the anti-cholinergic side effects of the tricyclic antidepressants; however, it may produce sedation (transient), dizziness, and ataxia. Side effects may be minimized by starting with low doses initially and then gradually increasing the dose. It also has very few drug interactions compared to the tricyclic antidepressants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pregabalin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    is, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , approved for the treatment of postherpetic neuralgia, and is now also being used off-label for the treatment of vulvar pain. Its side effects are similar to those of gabapentin. Pregabalin can be given less frequently (twice daily) than gabapentin (usually three times daily), but side effects can be more troublesome and it is a schedule V controlled substance. There is evidence that pregabalin is effective for pain reduction in a number of neuropathic pain problems (but none specific for vulvodynia). In diabetic neuropathy, there is a small crossover study with pregabalin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , favoring pregabalin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    at 50 mg orally at bedtime for three days, and then increase to 50 mg twice per day for three days, and then 50 mg three times per day. It may be increased in the same fashion to a maximum of 600 mg daily, if tolerated. Common side effects include dizziness, somnolence, ataxia, peripheral edema of hands and feet, weight gain, blurred vision. If side effects are a problem, a slower increase may help the patient tolerate higher doses. Pregabalin should not be discontinued abruptly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Venlafaxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    can be helpful in some patients. It is started at 37.5 mg orally two times per day and increased by 37.5 mg every four days to a maximum of 375",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    a sustained release form may be substituted for easier dosing. Venlafaxine is not effective as an analgesic at doses under 250 mg. Side effects and drug interactions are very common; prescription of this drug may be aided by consultation with clinicians thoroughly familiar with its use. It should not be discontinued abruptly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Duloxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     Duloxetine",
"    </a>",
"    has been used off-label for treatment of vulvar pain. There is evidence for the use of duloxetine in neuropathic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/21\">",
"     21",
"    </a>",
"    ]. We start treatment at 20 mg orally each day for seven days and then increase by 20 mg each week to 60 mg daily. This is the minimal effective dose for treatment of pain (but not for treatment of depression). Duloxetine can be increased by 20 mg weekly to a maximum dose of 120",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Because side effects and drug interactions are common, this drug should be prescribed by clinicians familiar with its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen therapy can be useful in women with vestibulodynia and atrophic changes. In our experience, the low dose vaginal estrogen ring and tablets are helpful, but sometimes do not provide an adequate estrogen effect to the vestibule itself. We suggest treatment with a quarter teaspoon of estradiol cream 0.1 percent to the vestibule daily for four weeks in order to achieve the desired effect; the frequency can then be decreased to one to two times weekly. We prefer estradiol over conjugated equine estrogen cream, as it has less local side effects. Estradiol cream can also be compounded if necessary to eliminate reaction to preservatives and irritants in the base of conventional prescription cream. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link\">",
"     \"Treatment of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other drugs or drug combinations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       Enoxaparin",
"      </a>",
"      (40 mg subcutaneous daily for 90 days) was compared with placebo in a randomized trial of 40 women with severe localized provoked vulvodynia and showed a modest 20 percent reduction in vulvar pain (75 versus 28 percent of participants) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/27\">",
"       27",
"      </a>",
"      ]. After 90 days of treatment, only 18 percent of the women treated with enoxaparin reported painless intercourse versus 8 percent in the placebo group. The possible mechanism of this therapy is an inhibition of heparanase activity in the vestibular tissue, which has been found to be increased in women with vulvodynia in a few reports [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. Given the modest effect and the risk of bleeding complications, further study is needed to evaluate this treatment.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       Capsaicin",
"      </a>",
"      , the active irritant in hot peppers, has been evaluated in a number of studies, with varying results [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]. Most women are unwilling to tolerate the extreme burning caused by the topical application of this drug.",
"     </li>",
"     <li>",
"      A variety of topical compounded creams has been used in order to avoid the side effects of oral medications, containing varying concentrations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"       ketoprofen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      . Some examples include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      3 percent and 5 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      5 percent in a hypoallergenic base",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      6 percent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      10 percent, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"       ketoprofen",
"      </a>",
"      10 percent in a neutral base",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       Ketamine",
"      </a>",
"      2 percent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      2 percent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      2 percent, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"       ketoprofen",
"      </a>",
"      10 percent in a hypoallergenic base",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local injection of botulinum toxin type A (BTX-A) appears to be effective; experience is limited to case reports and two small randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/33-39\">",
"       33-39",
"      </a>",
"      ]. It is expensive and typically not covered by insurance when used for this indication. BTX-A has been injected directly into the vestibule for localized provoked vulvodynia and has been used for trigger point injections into muscles of the pelvic floor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5305?source=see_link\">",
"       \"Treatment of myofascial pelvic pain syndrome in women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In women with symptoms suggestive of semen allergy (ie, vaginal burning, swelling, and itching postcoitally), treatment is targeted at the allergic symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2392?source=see_link\">",
"       \"Allergic reactions to seminal plasma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is minimal evidence that topical corticosteroids alone [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/40\">",
"       40",
"      </a>",
"      ], antiinflammatory agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/41\">",
"       41",
"      </a>",
"      ], topical testosterone, antibiotics, retinoid compounds [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/42\">",
"       42",
"      </a>",
"      ] or topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/43\">",
"       43",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/44\">",
"       44",
"      </a>",
"      ] are effective. Nitroglycerin-related headache makes this therapy impractical.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       Tramadol",
"      </a>",
"      and some anticonvulsants (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      ) appear to be effective for relief of neuropathic pain; they have not been studied as a treatment for vulvar pain, but, in our experience, have been helpful to women with vulvodynia.",
"     </li>",
"     <li>",
"      There is a role for short-term use of an opioid, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      , while awaiting the efficacy of a longer acting medication, such as one of the tricyclic antidepressants. Long-term use of opioids for treatment of chronic pain can be associated with adverse effects, but may be utilized in some situations to meet treatment goals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the treatment of chronic pain\", section on 'Opioids'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Local injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with longstanding pain unresponsive to other interventions, nerve block can be helpful. It is generally performed by an anesthesiologist or other expert in pain management.",
"   </p>",
"   <p>",
"    The effectiveness of local nerve block was illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 22 women evaluated infiltration of the vestibule with a solution of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      acetate (MA) (40 mg) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      chlorohydrate (LC) (10 mg in saline) injected with a 26 gauge needle attached to a 2.5 mL syringe [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/45\">",
"       45",
"      </a>",
"      ]. The volume of injection was 1 mL on Day 1 (ie, MA 40 mg, LC 10 mg), 0.5 mL on Day 8 (ie, MA 20 mg, LC 5 mg), and 0.3 mL on Day 15 (ie, MA 12 mg, LC 3 mL). Seven women had complete remission of symptoms, eight had marked improvement, and seven had no improvement over nine months. With this regimen, it is important to massage the tissue into which the drug is injected to avoid precipitation of drug.",
"     </li>",
"     <li>",
"      Another observational study including 27 women reported serial nerve blocks (combination of caudal epidural, pudendal, and local infiltration) significantly improved vestibular pain, but follow-up was limited to only 8 to 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ganglion impar blocks are done only by anesthesiologists and pain management experts and have been tried for vulvar pain. This type of block consists of steroid injection around the terminal branch of the sympathetic chain in the presacral space. It has been performed with encouraging results for unprovoked vulvodynia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/47-50\">",
"     47-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2352170\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no surgical intervention for generalized unprovoked vulvodynia. Women who report generalized unprovoked vulvar pain unresponsive to medication and physical therapy may suffer from pudendal nerve entrapment. Diagnosis may be made clinically by the above history or by testing with electromyography by specialists. Block of the pudendal nerve at its origin can be diagnostic and therapeutic. Transgluteal decompression of an entrapped pudendal nerve can also be therapeutic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical techniques for local provoked vulvodynia include Woodruff's original perineoplasty, vestibulectomy only, posterior vestibulectomy, modified vestibulectomy, simplified vestibulectomy, and vestibuloplasty (subsequently found ineffective) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/55-60\">",
"     55-60",
"    </a>",
"    ]. Definition of surgical outcome varies; a major problem is that there are no randomized studies comparing operative technique. Although many published series suggest good results from operative treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/16,22,61-63\">",
"     16,22,61-63",
"    </a>",
"    ], most opinion leaders still recommend surgery as the last resort. Other treatment modalities (behavioral therapy, sexual counseling and biofeedback) are often needed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/64\">",
"     64",
"    </a>",
"    ]. Surgery is more effective for secondary than primary localized vulvodynia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pelvic floor muscle rehabilitation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4497908\">",
"    <span class=\"h1\">",
"     COMPLEMENTARY OR ALTERNATIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of complementary and alternative treatments is not clear, but we consider acupuncture, yoga, and massage therapy to be helpful adjuncts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16249/abstract/65\">",
"     65",
"    </a>",
"    ]. Nevertheless, focusing on a multimodal approach, we have found CBT to be a helpful tool in the armamentarium of women with vulvodynia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=see_link\">",
"       \"Patient information: Vulvar pain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of vulvodynia is empiric and involves patient education, behavioral modification, emotional support, medications, and other approaches to treat the pain. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with provoked localized vulvar pain, with or without pelvic floor hypertonicity, we suggest pelvic floor muscle rehabilitation and topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ointment as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Topical anesthetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with unprovoked vulvar pain, we suggest tricyclic antidepressants as first line pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We start at 10 mg once a day at bedtime and increase the dose by 10 mg every five days to 100 to 150 mg at bedtime. A dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      100 to 150 mg for three months without improvement would prompt us to taper and then discontinue the drug, and switch to another agent. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Tricyclic antidepressants'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Our second-line choice is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Gabapentin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Using combinations of drugs may be effective when single agent therapy fails, but must be done cautiously, given the significant side effects of these drugs. Our preference is to start with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and gabapentin.",
"     </li>",
"     <li>",
"      Local nerve block may be effective for women who have not achieved adequate pain relief from pharmacologic therapy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Local injections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/1\">",
"      Harlow BL, Stewart EG. A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? J Am Med Womens Assoc 2003; 58:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/2\">",
"      Vase L, Riley JL 3rd, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 2002; 99:443.",
"     </a>",
"    </li>",
"    <li>",
"     International Society for the Study of Vulvovaginal Disease, XVII World Congress, jointly sponsored by the American College of Obstetricians and Gynecologists, October 12-16, 2003, Salvador, Brazil.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/4\">",
"      Moyal-Barracco M, Lynch PJ. 2003 ISSVD terminology and classification of vulvodynia: a historical perspective. J Reprod Med 2004; 49:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/5\">",
"      Andrews JC. Vulvodynia: An evidence-based approach to medical management. j clin outcome manag 2010; 17:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/6\">",
"      Backman H, Widenbrant M, Bohm-Starke N, Dahlof LG. Combined physical and psychosexual therapy for provoked vestibulodynia-an evaluation of a multidisciplinary treatment model. J Sex Res 2008; 45:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/7\">",
"      Dell JR, Parsons CL. Multimodal therapy for interstitial cystitis. J Reprod Med 2004; 49:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/8\">",
"      Harlow BL, Abenhaim HA, Vitonis AF, Harnack L. Influence of dietary oxalates on the risk of adult-onset vulvodynia. J Reprod Med 2008; 53:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/9\">",
"      Greenstein A, Militscher I, Chen J, et al. Hyperoxaluria in women with vulvar vestibulitis syndrome. J Reprod Med 2006; 51:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/10\">",
"      Bohm-Starke N, Johannesson U, Hilliges M, et al. Decreased mechanical pain threshold in the vestibular mucosa of women using oral contraceptives: a contributing factor in vulvar vestibulitis? J Reprod Med 2004; 49:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/11\">",
"      Goldstein AT, Burrows L. Vulvodynia. J Sex Med 2008; 5:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/12\">",
"      Mandal, D. Diagnosis and management of vulvodynia should include biopsy and histological examination: reply from authors. Br J Dermatol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/13\">",
"      Glazer HI, Rodke G, Swencionis C, et al. Treatment of vulvar vestibulitis syndrome with electromyographic biofeedback of pelvic floor musculature. J Reprod Med 1995; 40:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/14\">",
"      McKay E, Kaufman RH, Doctor U, et al. Treating vulvar vestibulitis with electromyographic biofeedback of pelvic floor musculature. J Reprod Med 2001; 46:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/15\">",
"      Glazer HI. Dysesthetic vulvodynia. Long-term follow-up after treatment with surface electromyography-assisted pelvic floor muscle rehabilitation. J Reprod Med 2000; 45:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/16\">",
"      Bergeron S, Khalif&eacute; S, Glazer HI, Binik YM. Surgical and behavioral treatments for vestibulodynia: two-and-one-half year follow-up and predictors of outcome. Obstet Gynecol 2008; 111:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/17\">",
"      Reed BD, Haefner HK, Edwards L. A survey on diagnosis and treatment of vulvodynia among vulvodynia researchers and members of the International Society for the Study of Vulvovaginal Disease. J Reprod Med 2008; 53:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/18\">",
"      Haefner HK, Collins ME, Davis GD, et al. The vulvodynia guideline. J Low Genit Tract Dis 2005; 9:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/19\">",
"      Hartmann D, Strauhal MJ, Nelson CA. Treatment of women in the United States with localized, provoked vulvodynia: practice survey of women's health physical therapists. J Reprod Med 2007; 52:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/20\">",
"      Danielsson I, Torstensson T, Brodda-Jansen G, Bohm-Starke N. EMG biofeedback versus topical lidocaine gel: a randomized study for the treatment of women with vulvar vestibulitis. Acta Obstet Gynecol Scand 2006; 85:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/21\">",
"      Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/22\">",
"      Foster DC, Kotok MB, Huang LS, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol 2010; 116:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/23\">",
"      Munday PE. Response to treatment in dysaesthetic vulvodynia. J Obstet Gynaecol 2001; 21:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/24\">",
"      Harris G, Horowitz B, Borgida A. Evaluation of gabapentin in the treatment of generalized vulvodynia, unprovoked. J Reprod Med 2007; 52:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/25\">",
"      Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol 2008; 112:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/26\">",
"      Bansal D, Bhansali A, Hota D, et al. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 2009; 26:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/27\">",
"      Farajun Y, Zarfati D, Abramov L, et al. Enoxaparin treatment for vulvodynia: a randomized controlled trial. Obstet Gynecol 2012; 120:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/28\">",
"      Bornstein J, Cohen Y, Zarfati D, et al. Involvement of heparanase in the pathogenesis of localized vulvodynia. Int J Gynecol Pathol 2008; 27:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/29\">",
"      Bornstein J, Goldschmid N, Sabo E. Hyperinnervation and mast cell activation may be used as histopathologic diagnostic criteria for vulvar vestibulitis. Gynecol Obstet Invest 2004; 58:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/30\">",
"      Bergeron S, Binik YM, Khalif&eacute; S, Pagidas K. Vulvar vestibulitis syndrome: a critical review. Clin J Pain 1997; 13:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/31\">",
"      Steinberg AC, Oyama IA, Rejba AE, et al. Capsaicin for the treatment of vulvar vestibulitis. Am J Obstet Gynecol 2005; 192:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/32\">",
"      Murina F, Radici G, Bianco V. Capsaicin and the treatment of vulvar vestibulitis syndrome: a valuable alternative? MedGenMed 2004; 6:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/33\">",
"      Yoon H, Chung WS, Shim BS. Botulinum toxin A for the management of vulvodynia. Int J Impot Res 2007; 19:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/34\">",
"      Gunter J, Brewer A, Tawfik O. Botulinum toxin a for vulvodynia: a case report. J Pain 2004; 5:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/35\">",
"      Dykstra DD, Presthus J. Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med 2006; 51:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/36\">",
"      Brown CS, Glazer HI, Vogt V, et al. Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. J Reprod Med 2006; 51:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/37\">",
"      Abbott JA, Jarvis SK, Lyons SD, et al. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 2006; 108:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/38\">",
"      Presthus, JB, Dykstra, DD. Botulinum toxin therapy for vulvodynia. NVA News 2007; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/39\">",
"      Bertolasi L, Frasson E, Cappelletti JY, et al. Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome. Obstet Gynecol 2009; 114:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/40\">",
"      Munday PE. Treatment of vulval vestibulitis with a potent topical steroid. Sex Transm Infect 2004; 80:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/41\">",
"      Kamdar N, Fisher L, MacNeill C. Improvement in vulvar vestibulitis with montelukast. J Reprod Med 2007; 52:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/42\">",
"      Friedrich EG Jr. Therapeutic studies on vulvar vestibulitis. J Reprod Med 1988; 33:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/43\">",
"      Walsh KE, Berman JR, Berman LA, Vierregger K. Safety and efficacy of topical nitroglycerin for treatment of vulvar pain in women with vulvodynia: a pilot study. J Gend Specif Med 2002; 5:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/44\">",
"      Meltzer-Brody SE, Zolnoun D, Steege JF, et al. Open-label trial of lamotrigine focusing on efficacy in vulvodynia. J Reprod Med 2009; 54:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/45\">",
"      Murina F, Tassan P, Roberti P, Bianco V. Treatment of vulvar vestibulitis with submucous infiltrations of methylprednisolone and lidocaine. An alternative approach. J Reprod Med 2001; 46:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/46\">",
"      Rapkin AJ, McDonald JS, Morgan M. Multilevel local anesthetic nerve blockade for the treatment of vulvar vestibulitis syndrome. Am J Obstet Gynecol 2008; 198:41.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/47\">",
"      Rigaud J, Delavierre D, Sibert L, Labat JJ. [Sympathetic nerve block in the management of chronic pelvic and perineal pain]. Prog Urol 2010; 20:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/48\">",
"      Agarwal-Kozlowski K, Lorke DE, Habermann CR, et al. CT-guided blocks and neuroablation of the ganglion impar (Walther) in perineal pain: anatomy, technique, safety, and efficacy. Clin J Pain 2009; 25:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/49\">",
"      Toshniwal GR, Dureja GP, Prashanth SM. Transsacrococcygeal approach to ganglion impar block for management of chronic perineal pain: a prospective observational study. Pain Physician 2007; 10:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/50\">",
"      Lim SJ, Park HJ, Lee SH, Moon DE. Ganglion impar block with botulinum toxin type a for chronic perineal pain -a case report-. Korean J Pain 2010; 23:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/51\">",
"      Robert R, Labat JJ, Bensignor M, et al. Decompression and transposition of the pudendal nerve in pudendal neuralgia: a randomized controlled trial and long-term evaluation. Eur Urol 2005; 47:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/52\">",
"      Lefaucheur JP, Labat JJ, Amarenco G, et al. What is the place of electroneuromyographic studies in the diagnosis and management of pudendal neuralgia related to entrapment syndrome? Neurophysiol Clin 2007; 37:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/53\">",
"      Robert R, Labat JJ, Riant T, et al. Neurosurgical treatment of perineal neuralgias. Adv Tech Stand Neurosurg 2007; 32:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/54\">",
"      Labat JJ, Riant T, Robert R, et al. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). Neurourol Urodyn 2008; 27:306.",
"     </a>",
"    </li>",
"    <li>",
"     Horowitz IR, Buscema J, Woodruff JD. Surgical Conditions of the Vulva. In: Te Linde's Operative Gynecology, 8th ed, Rock JA, Thompson JD.  (Eds), Lippincott-Raven, Philadelphia 1997. p.903.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/56\">",
"      Bergeron S, Bouchard C, Fortier M, et al. The surgical treatment of vulvar vestibulitis syndrome: a follow-up study. J Sex Marital Ther 1997; 23:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/57\">",
"      Kehoe S, Luesley D. Vulvar vestibulitis treated by modified vestibulectomy. Int J Gynaecol Obstet 1999; 64:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/58\">",
"      Goldstein A. Surgical techniques: Surgery for Vulvar Vestibulitis syndrome. J Sex Med 2006; 3:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/59\">",
"      Goetsch MF. Simplified surgical revision of the vulvar vestibule for vulvar vestibulitis. Am J Obstet Gynecol 1996; 174:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/60\">",
"      Bornstein J, Zarfati D, Goldik Z, Abramovici H. Perineoplasty compared with vestibuloplasty for severe vulvar vestibulitis. Br J Obstet Gynaecol 1995; 102:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/61\">",
"      Bohm-Starke N, Rylander E. Surgery for localized, provoked vestibulodynia: a long-term follow-up study. J Reprod Med 2008; 53:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/62\">",
"      Goldstein AT, Klingman D, Christopher K, et al. Surgical treatment of vulvar vestibulitis syndrome: outcome assessment derived from a postoperative questionnaire. J Sex Med 2006; 3:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/63\">",
"      Bergeron S, Binik YM, Khalif&eacute; S, et al. A randomized comparison of group cognitive--behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. Pain 2001; 91:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/64\">",
"      Tommola P, Unkila-Kallio L, Paavonen J. Surgical treatment of vulvar vestibulitis: a review. Acta Obstet Gynecol Scand 2010; 89:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16249/abstract/65\">",
"      Nunns D, Mandal D, Byrne M, et al. Guidelines for the management of vulvodynia. Br J Dermatol 2010; 162:1180.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5438 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16249=[""].join("\n");
var outline_f15_55_16249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4070616\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4070835\">",
"      Diagnosis and evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4071161\">",
"      Vulvar care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sexual and psychological issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4071285\">",
"      Role of oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4071325\">",
"      Multidisciplinary approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PELVIC FLOOR MUSCLE REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Topical anesthetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pregabalin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Venlafaxine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Duloxetine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other drugs or drug combinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Local injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2352170\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4497908\">",
"      COMPLEMENTARY OR ALTERNATIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5438\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5438|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/2/7211\" title=\"table 1\">",
"      Neurologic causes vulvar pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/49/36635\" title=\"table 2\">",
"      Healthy vulval hygiene practice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2392?source=related_link\">",
"      Allergic reactions to seminal plasma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43032?source=related_link\">",
"      Approach to the woman with sexual pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8295?source=related_link\">",
"      Clinical manifestations and diagnosis of generalized vulvodynia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/46/37609?source=related_link\">",
"      Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37876?source=related_link\">",
"      Desquamative inflammatory vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23128?source=related_link\">",
"      Differential diagnosis of sexual pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=related_link\">",
"      Management of interstitial cystitis/bladder pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=related_link\">",
"      Patient information: Vulvar pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5305?source=related_link\">",
"      Treatment of myofascial pelvic pain syndrome in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=related_link\">",
"      Vulvar lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_55_16250="Psychosocial and other social factors in acute myocardial infarction";
var content_f15_55_16250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychosocial and other social factors in acute myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16250/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16250/contributors\">",
"     Geoffrey H Tofler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16250/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16250/contributors\">",
"     Jonathan M Silver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/55/16250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/55/16250/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/55/16250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although acute and chronic stress have long been suspected as risk factors for myocardial infarction (MI) and sudden cardiac death, the presence of a causal link has been viewed with skepticism. However, an increasing body of evidence supports a link even though the mechanisms remain uncertain. Recent observations have opened the broad field of acute risk to study and have highlighted the potential role of psychosocial factors in acute disease onset and prognosis after MI. As an example, ST elevation (Q-wave) MI is now recognized to be preceded by coronary thrombosis, which is in turn associated with plaque fissuring [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Plaque disruption and thrombosis frequently occurs at the site of a previously mild stenosis, suggesting that the transformation from a stable to unstable plaque occurs acutely (",
"    <a class=\"graphic graphic_algorithm graphicRef77739 \" href=\"UTD.htm?39/7/40051\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CIRCADIAN VARIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The circadian variation in frequency of MI, sudden cardiac death, and myocardial ischemia is characterized by a morning peak. A meta-analysis of 66,635 patients with an acute MI and 19,390 patients with sudden death reported an excess of MIs (relative risk 1.38) and sudden deaths (relative risk 1.29) between the hours of 6 am and noon compared to the rest of the day (",
"    <a class=\"graphic graphic_figure graphicRef56626 graphicRef59140 \" href=\"UTD.htm?16/50/17185\">",
"     figure 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The circadian variation in event frequency suggests that cardiac events may be triggered by external activities, particularly those activating the sympathetic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/5\">",
"     5",
"    </a>",
"    ]. Support for this comes from one study of 1225 patients which reported an absence of a circadian variation in diabetics, particularly those with evidence of cardiac autonomic neuropathy who have absent heart rate variability [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/6\">",
"     6",
"    </a>",
"    ], and those taking beta blockers or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    at the time of admission for an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=see_link\">",
"     \"Diabetic autonomic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A circadian variability in fibrinolytic capacity may be another factor contributing to the morning increase in MI. Among patients with stable coronary heart disease, plasminogen activator inhibitor-1 activity peaks in the early morning while tissue plasminogen activator activity is at its nadir; treatment with a beta blocker ameliorated this relatively prothrombotic state [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=see_link\">",
"     \"Fibrinolytic markers and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRIGGERING OF ACUTE MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Multicenter Investigation of the Limitation of Infarct Size (MILIS) indicated that among 849 patients with acute MI, 48 percent described one or more possible triggers, the most common of which was emotional upset (14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/9\">",
"     9",
"    </a>",
"    ]. Other studies have identified possible triggers in up to 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Life events and other crises",
"    </span>",
"    &nbsp;&mdash;&nbsp;One report in 1975 found that stressful life events occurred among 40 of 100 sudden death victims in the 24 hours preceding death [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/13\">",
"     13",
"    </a>",
"    ]. Since this and related studies are subject to the criticism of biased recall by relatives or friends of the victims, prospective studies are somewhat more reliable. In a large cohort of middle-aged widowers, for example, a 40 percent increase in the mortality rate in the first 6 months was observed following bereavement; more than half of which was attributed to cardiovascular causes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/14\">",
"     14",
"    </a>",
"    ]. It is unclear how much of this increase in mortality was due to lifestyle changes during the grieving period rather than to stress per se.",
"   </p>",
"   <p>",
"    The INTERHEART study was a worldwide study of cardiac risk factors comparing over 11,000 patients with a first MI with over 13,000 matched controls from 52 countries on six continents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/15\">",
"     15",
"    </a>",
"    ]. In an analysis of psychosocial factors, stressful life events had occurred more frequently within the prior year among patients than among controls (16.1 versus 13.0 percent; odds ratio 1.48; 95% CI 1.33-1.64). Stressful life events specified included marital separation or divorce, loss of job or retirement, loss of crop or business failure, violence, major intrafamily conflict, major personal injury or illness, death or major illness of a close family member, death of a spouse, or other major stress.",
"   </p>",
"   <p>",
"    An increase in cardiovascular events has also been associated with disasters. This can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the five days after the 1981 Athens earthquake, the incidence of cardiac deaths rose from the normal average of 2.6 deaths per day to an average of 5.4, with a peak of 8 deaths per day [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increased relative risk of acute MI (2.4) and cardiovascular death was observed after the 1994 Los Angeles earthquake, which occurred in the early morning, compared to the week before the disaster [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/17\">",
"       17",
"      </a>",
"      ]. In contrast, the San Francisco earthquake of 1989, which occurred in the afternoon, was not associated with an increase in acute MIs; these data suggest that an MI is more likely to occur if an extreme emotional stress is superimposed upon the normal circadian pattern or a second trigger, such as abrupt awakening in the morning [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During the initial eight days after six blizzards in Massachusetts from 1974 to 1978, a 22 percent increase in ischemic deaths per day was reported in comparison to preceding and subsequent control weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During the six weeks immediately following the Hanshin-Awaji, Japan earthquake there were 10 cardiovascular or sudden deaths compared to three during the same period in the previous year [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/20\">",
"       20",
"      </a>",
"      ]. A study of 42 elderly patients with well controlled hypertension who lived near the epicenter reported that one to two weeks after the earthquake (when aftershocks were frequent), there were transient increases in blood pressure, blood viscosity determinants, and fibrin turnover.",
"     </li>",
"     <li>",
"      The 1991 Iraq war also provided an opportunity to study the cardiovascular effects of psychological stress. During the first week of missile attacks on Israel, 20 civilians developed an acute infarction in the area served by one hospital, compared to only eight during a control period [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was a statistically significant 49 percent increase in patients admitted with MI through 16 emergency departments within a 50-mile radius of the World Trade Center in the 60 days after September 11, 2001, compared with the 60 days beforehand (118 MIs after versus 79 before) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it is tempting to attribute the increase in cardiovascular events following these traumas to mental stress, the role of other factors such as unaccustomed physical activity, altered sleep patterns and diet needs to be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to acute events, chronic levels of stress may also be associated with acute coronary syndromes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort study of 13,609 men and women, mean age 45 years, a questionnaire was used to detect levels of chronic psychosocial stress, which were high in 2019 (15 percent), moderate in 765 (6 percent), and low in 10,825 (80 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/23\">",
"       23",
"      </a>",
"      ]. At a mean follow-up of 21 years, 2731 patients (20 percent) suffered a first cardiovascular event (fatal or nonfatal myocardial infarction or stroke, angina pectoris, or acute coronary syndrome). The risk of a first cardiovascular event was significantly higher for those with moderate or high stress, though the magnitude of the increase was small (adjusted risk ratio 1.14). For women analyzed separately, there was no increase in risk after adjustment.",
"     </li>",
"     <li>",
"      A report comparing 130 patients with an acute MI or unstable angina to 102 control subjects hospitalized for acute trauma found that cardiac patients had higher levels of social isolation, self-blame and avoidance, and more painful life experiences compared with controls [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/24\">",
"       24",
"      </a>",
"      ]. High levels of psychologic distress were detectable in about 75 percent of cardiac patients.",
"     </li>",
"     <li>",
"      In the worldwide INTERHEART study, sources of chronic stress were divided into work stress, home stress, and financial stress [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/15\">",
"       15",
"      </a>",
"      ]. Patients with a first MI reported significantly more stress in each of these categories than controls. The proportion of MI patients experiencing moderate or severe work or home stress varied widely among regions, from 43.8 percent in North America to 15.6 percent in China and Hong Kong.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Personality and mood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the role of personality in the etiology of coronary artery disease have yielded controversial results. However, there is increasing evidence that hostility, cynicism, and anger form a critical \"toxic\" component of type A behavior that is associated with enhanced cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety as a cardiovascular risk factor has not been studied as extensively as other psychosocial factors. Two representative studies suggest an association:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During a two-year follow-up of 33,999 male health professionals in the United States who were aged 42 to 77 years and initially free of diagnosed disease, the age-adjusted relative risk of fatal cardiovascular disease was three-fold greater for those having the highest levels of phobic anxiety compared to those with the lowest levels [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 735 men (mean age 60 years) without cardiovascular disease or diabetes, the presence of overall anxiety, as assessed by four scales which included phobia, independently and significantly predicted the development of myocardial infarction during a mean follow-up of 12.4 years [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of evidence supports depression as a risk factor for cardiovascular disease, both in otherwise healthy subjects and in those with known cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/28-34\">",
"     28-34",
"    </a>",
"    ]. Several potential mechanisms have been proposed, however their relative contribution requires further elucidation. The potential mechanisms include hypothalamic-pituitary-adrenal axis dysfunction, inflammatory and prothrombotic changes, dietary factors, low omega-3 fatty acid levels, reduced heart rate variability and adverse behavior including medication non-adherance, smoking and physical inactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following studies support the relationship between depression and cardiovascular disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest analysis of this issue comes from data on over 93,000 postmenopausal women aged 50 to 79 years participating in the Women's Health Initiative Observational Study [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/29\">",
"       29",
"      </a>",
"      ]. At baseline, 16 percent of study participants were found to be currently depressed and 12 percent to have a history of depression. At four years, patients with current or previous depression had significantly higher rates of cardiovascular death (0.79 versus 0.52 percent) and all-cause mortality (2.87 versus 2.18 percent) than those without depression.",
"     </li>",
"     <li>",
"      In the worldwide INTERHEART study, depression was significantly more common among patients with a first MI than among controls (24.0 versus 17.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Heart and Soul study of patients with stable coronary artery disease, baseline depressive symptoms assessed using the Patient Health Questionnaire (PHQ) were predictive of subsequent age-adjusted annualized cardiovascular events (10% for PHQ score &ge;10 versus 6.7% without depressive symptoms, HR 1.5, p=0.002). Adjustment for biological factors attenuated the association, which was no longer significant after further adjustment for potential behavioral mediators, in particular physical inactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/35\">",
"       35",
"      </a>",
"      ]. These findings suggest the need for further investigation of exercise as a possible intervention to ameliorate the link between depression and cardiovascular risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The severity of depression has also been correlated with cardiovascular risk. This was illustrated in a prospective cohort of 4493 elderly subjects (&ge;65 years of age) in the Cardiovascular Health Study who were initially free of cardiovascular disease at baseline and were followed for six years, found that each 5-unit increase in depression score was associated with an adjusted hazard ratio of 1.15 and 1.16 for the development of coronary heart disease and all-cause mortality, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/33\">",
"     33",
"    </a>",
"    ]. Those with the highest depression scores had a 40 and 60 percent increased risk of coronary disease and death compared to those with the lowest scores. A similar graded relationship was noted for the occurrence of MI in the Baltimore Epidemiologic Catchment Area study; the relationship was independent of coronary risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more complex relationship was noted in the Systolic Hypertension in older adults. Program (SHEP) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/36\">",
"     36",
"    </a>",
"    ]. In this trial, 4736 subjects aged 60 years or more with isolated systolic hypertension were followed for an average of 4.5 years, with depressive symptoms being assessed by six month questionnaires. Baseline levels of depressive symptoms did not predict future cardiovascular events; however there was an increase in depression score prior to MI, stroke or death. One study found that in men, but not women, over 70 years the recent onset of depression, but not chronic depression, was associated with an increased risk of cardiovascular mortality (relative risk 1.75), cardiovascular and coronary heart disease events (relative risk 2.07 and 2.03, respectively), and all cause mortality (relative risk 1.4) (",
"    <a class=\"graphic graphic_figure graphicRef64348 \" href=\"UTD.htm?29/57/30621\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Anger",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that anger can have a deleterious effect on the cardiovascular system [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients with trait anger have a relatively stable personality, but manifest rage and fury more often, more intensely, and have longer-lasting episodes. The relationship between anger and coronary heart disease was evaluated in the Atherosclerosis Risk in Communities (ARIC) trial of 12,986 men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/39\">",
"     39",
"    </a>",
"    ]. Compared to normotensive subjects with low trait anger, normotensive subjects with high trait anger were at higher risk for all coronary heart disease events, including acute MI, cardiac mortality, silent MI, or coronary revascularization (hazard ratio 2.20), and for hard cardiac events of acute MI or cardiac mortality (hazard ratio 2.69). There was no relationship between trait anger and risk of coronary heart disease in hypertensive individuals.",
"   </p>",
"   <p>",
"    Anger in response to stress may be of particular importance for the development of premature MI in young men. As an example, one longitudinal study of 1055 young medical students established anger reactions to stress by self-reporting on a questionnaire administered in medical school [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/40\">",
"     40",
"    </a>",
"    ]. After a median follow-up of 36 years, those with the highest level of anger, compared to those with lower levels, had a significant increased risk of premature cardiovascular disease developing before the age of 55 (adjusted relative risk 3.1), coronary heart disease (adjusted relative risk 3.5), and MI (relative risk 6.4).",
"   </p>",
"   <p>",
"    An episode of anger may also trigger an acute MI. The Determinants of Myocardial Infarction Onset Study interviewed 1623 patients within one week of MI: 2.4 percent reported episodes of anger within the two hours prior to MI onset [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/11\">",
"     11",
"    </a>",
"    ]. The level of anger corresponded on a scale to the subjects feeling \"very angry, body tense, clenching fists or teeth.\" The most frequent causes of anger were arguments with family members (25 percent), conflicts at work (22 percent), and legal problems (8 percent). The relative risk of MI following episodes of anger was 2.3, especially during the first two hours after an outburst of anger.",
"   </p>",
"   <p>",
"    The relative risk for anger was significantly lower among regular users of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (1.4 versus 2.9 in nonusers) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/11\">",
"     11",
"    </a>",
"    ]. A nonsignificant trend for the relative risk to be lower in regular users of beta blockers versus nonusers was also observed.",
"   </p>",
"   <p>",
"    In the Stockholm Heart Epidemiology Program, the relative risk was nine-fold for anger as a trigger [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Seasonal pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several series have demonstrated a seasonal pattern of deaths from MI, with more fatal events (20 to 30 percent variation) occurring in the winter than the summer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. As an example, a recent report from the National Registry of Myocardial Infarction evaluated 259,891 cases of acute MI from 1474 hospitals during a 25 month period; approximately 53 percent more MIs occurred in the winter or spring compared to the summer (p&lt;0.05) (",
"    <a class=\"graphic graphic_figure graphicRef82538 \" href=\"UTD.htm?0/18/302\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/42\">",
"     42",
"    </a>",
"    ]. The trends were independent of gender, geographic location, age, and the type of MI (ST elevation or non-ST elevation). In-hospital fatality rates for MI also followed a seasonal pattern, with a peak of 9 percent in winter and a nadir in the spring (8.4 percent). However, a seasonal pattern is absent in diabetics or those taking beta blockers or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , suggesting an important role for the sympathetic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar association between the season and death from MI was also noted in another study of 300,000 deaths from MI or stroke in the Canadian Mortality database; however, in this study there was a relationship between mortality and age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/44\">",
"     44",
"    </a>",
"    ]. Deaths from MI were highest in January and lowest in September, with a relative risk difference of 18.6 percent. The seasonal mortality variation (winter versus summer) increased with increasing age; for those &lt;65, 65 to 74, 75 to 84 and &gt;85 mortality was 5.8, 8.3, 13.4, and 15.8 percent, respectively.",
"   </p>",
"   <p>",
"    An interesting explanation for the association of coronary disease with the winter months was noted by the Eurowinter Group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/43\">",
"     43",
"    </a>",
"    ]. Among various European regions, the increase in coronary mortality was greater in warmer than in colder regions. The increase in risk was associated with low living-room temperatures and the wearing of fewer clothes when people went outdoors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other social factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to psychosocial factors, a number of other social factors have been identified as triggers of an acute MI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An acute coronary ischemic syndrome is the most common cardiac pathology associated with cocaine abuse and can occur with all routes of cocaine intake [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. In a survey of 10,085 adults between the ages of 18 and 45, cocaine use accounted for 25 percent of nonfatal MIs [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link\">",
"       \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smoking marijuana may be a rare trigger of MI. In one report of 3882 patients with an acute MI, 124 (3.2 percent) reported smoking marijuana in the prior year, 37 within 24 hours and nine within one hour [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/48\">",
"       48",
"      </a>",
"      ]. The risk of MI was increased 4.8-fold over baseline in the 60 minutes after marijuana use and then rapidly declined with time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=see_link\">",
"       \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exposure to particulate air pollution also may be associated with MI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H1267133#H1267133\">",
"       \"Overview of the possible risk factors for cardiovascular disease\", section on 'Air pollution'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      This may be due, in part to a sympathetic stress response, as detected by changes in heart rate variability, the production of cytokines, and an increased vulnerability to plaque rupture [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=see_link\">",
"       \"Heart rate variability: Technical aspects\"",
"      </a>",
"      .) In a study of 772 patients with an acute MI, the risk of an MI was increased in the two hours after exposure to elevated levels of fine particles in the air (odds ratio 1.48 compared to low levels of fine particles); this effect lasted for up to 24 hours after exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exposure to vehicular traffic has been implicated as an MI trigger. In one analysis, 691 patients with an acute MI were interviewed about activities during the four days preceding the event [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/53\">",
"       53",
"      </a>",
"      ]. Traffic exposure (defined as time spent in a vehicle) occurred during the hour before MI in 75 (12 percent) of 625 patients. Compared to the frequency of traffic exposure during the preceding three days, the likelihood of traffic exposure during the hour preceding MI was significantly increased (adjusted odds ratio 2.73).",
"     </li>",
"     <li>",
"      During the first hour after a heavy meal, there was a four-fold increase in relative risk of MI over baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A daily variation in MI and stroke has also been described with a peak incidence on Mondays [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. Holidays such as Christmas and New Year's day are also associated with increased cardiac mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several mechanisms by which emotional stress might trigger an acute MI (",
"    <a class=\"graphic graphic_algorithm graphicRef77739 \" href=\"UTD.htm?39/7/40051\">",
"     algorithm 1",
"    </a>",
"    ). The physiologic changes that have been described in the morning period of enhanced cardiovascular risk &mdash; increases in blood pressure, heart rate, vascular tone, and platelet aggregability &mdash; also may result from mental stress [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/58\">",
"     58",
"    </a>",
"    ]. These factors may all be related to abnormalities in autonomic tone and activation of sympathetic nervous system activity, which may enhance platelet aggregation and increase the susceptibility to serious ventricular arrhythmias.",
"   </p>",
"   <p>",
"    Support for the role of autonomic dysfunction comes from a study of 804 post MI patients with and without depression who underwent 24 hour ambulatory monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/59\">",
"     59",
"    </a>",
"    ]. Compared to patients without depression, those with minor or major depression had significantly decreased heart rate variability, indicating excessive sympathetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced parasympathetic tone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10601?source=see_link\">",
"     \"Heart rate variability: Use after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Myocardial ischemia and plaque rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental stress produces significant increases in heart rate and blood pressure that may lead to increased myocardial oxygen demand and plaque disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition to a rise in the rate pressure product, there is also evidence that mental stress may lead to a primary reduction in myocardial oxygen supply. Whereas coronary arteries of normal patients dilate during mental stress, impaired dilation and even constriction has been demonstrated in atherosclerotic arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vasoconstriction induced by stress may not be immediate. In a dog model, profound coronary vasoconstriction could be demonstrated two to three minutes following elicitation of anger [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/61\">",
"     61",
"    </a>",
"    ]. The vasoconstriction persisted well after heart rate and arterial blood pressure recovered.",
"   </p>",
"   <p>",
"    Myocardial ischemia, as evidenced by ST depression and more sensitive means such as radionuclide ventriculography and positron emission tomography, has been shown to be precipitated by psychologically stressful circumstances (eg, public speaking). One study, for example, found that among 29 patients with coronary artery disease with exercise induced wall motion abnormalities, 21 (72 percent) also exhibited wall motion abnormalities following mental stress [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/62\">",
"     62",
"    </a>",
"    ]. The ischemia was usually silent, often without ECG abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42135?source=see_link\">",
"     \"Silent myocardial ischemia: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Altered platelet activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although studies have not all shown consistent findings, mental stress enhances platelet aggregation secondary to sympathetic nervous system activation, and may promote mitogenic activity in plasma due to platelet-derived growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/63\">",
"     63",
"    </a>",
"    ]. There is a compensatory increase in fibrinolytic activity following acute stress, but a diminished fibrinolytic response due to endothelial dysfunction may lead to a prothrombotic imbalance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Altered cardiovascular risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the effects of chronic stress on cardiovascular risk factors are less clear, depressed mood scores and increased sympathetic reactivity have been associated with elevated cholesterol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/64\">",
"     64",
"    </a>",
"    ]. The interaction of altered sympathetic and cortisol levels with oxidized LDL and macrophage activation is receiving increasing attention [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The new information on triggering can be incorporated into a hypothesis of the progression of coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/65\">",
"     65",
"    </a>",
"    ]. The onset of MI may occur when a vulnerable atherosclerotic plaque disrupts in response to mental stress or anger that produces transient pressure surges or vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/5\">",
"     5",
"    </a>",
"    ]. If the plaque disruption is major with extensive exposure of collagen and atheromatous core contents to the lumen, this may lead immediately to occlusive thrombosis, with MI or sudden cardiac death. If the disruption is minor, it may lead to nonocclusive thrombosis. In this setting, the patient may be asymptomatic or develop unstable angina or non-ST elevation MI. The lesion may gradually heal with smooth muscle cell proliferation and a greater degree of stenosis. Alternatively, a further increase in coagulability or vasoconstriction may precipitate occlusive thrombosis, MI, and sudden cardiac death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DEPRESSION AND PSYCHOSOCIAL STRESS POST MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major depression develops in almost 20 percent of patients after MI, while over 33 percent have significant symptoms of depression soon after an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Depression is associated with poor compliance with recommendations for post MI therapy.",
"   </p>",
"   <p>",
"    In addition, depression (even if minimal) and other psychosocial stress factors, including hostility, social isolation, anxiety, anger, and marital stress, are related to a poor prognosis among patients recovering from an MI and to a reduced quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/66,68-74\">",
"     66,68-74",
"    </a>",
"    ]. As an example, a substudy from the GISSI-2 trial involved 2449 patients who completed a questionnaire dealing with psychological variables and were followed for six months after MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/75\">",
"     75",
"    </a>",
"    ]. The presence of extroversion and neurotic behavior had a protective effect, reducing risk by 40 percent. In contrast, the presence of vital exhaustion (excess fatigue, lack of energy, and sleep disturbances), depression, or lack of anxiety about the MI increased risk of death by two to three fold. The impact of these factors was comparable to that of well established clinical predictors such as left ventricular function, arrhythmia, and ineligibility for exercise testing.",
"   </p>",
"   <p>",
"    High levels of social support may influence mortality among depressed post-MI patients. A study of 887 patients who completed questionnaires seven days after an MI found that evidence of mild to moderate depression, present in 32 percent, was associated with increased cardiac mortality during a one year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/76\">",
"     76",
"    </a>",
"    ]. High levels of social support alone did not influence cardiac mortality, but were associated with improvements in depressive symptoms. In addition, high levels of social support appeared to buffer the impact of depression on mortality (",
"    <a class=\"graphic graphic_figure graphicRef76176 \" href=\"UTD.htm?40/33/41501\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A population-based case-control study found an association between MI and increased risk of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/77\">",
"     77",
"    </a>",
"    ]. The study identified 19,857 people aged 40 to 89 years who died by suicide, and randomly selected 190,058 controls matched by sex, date of birth, and calender time (control was alive on the day that the case committed suicide). Patients who suffered an MI and had no history of psychiatric illness were more than three times as likely to commit suicide within one month of the MI, compared with individuals who had no history of MI or psychiatric illness (incidence rate ratio 3.3, 95% CI 1.6-6.6). The risk of suicide remained high for at least five years after an MI. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous remission of depressive symptoms occurs in approximately one-half of cases of post-MI depression; the other cases either persist or remit and relapse within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]. This suggests that a substantial number of patients may benefit from treatment of depression following an MI. Standard treatment of depression can include psychotherapy, drug therapy, or both; the efficacy of these therapies in non-post-MI patients is similar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .) A number of patients with increased stress (without depression) post MI may also benefit from psychosocial interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Psychosocial interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial interventions have been evaluated for efficacy in both depressive symptoms and cardiovascular outcomes. Initial nonrandomized studies suggested that targeted stress reduction post-MI may have cardiovascular benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. In one report, stress assessments were made before discharge and by telephone on a monthly basis in 461 men with a recent MI; those determined to have high stress levels received outpatient visits from nurses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/82\">",
"     82",
"    </a>",
"    ]. This intervention was associated with a 41 percent reduction in cardiac mortality and a 46 percent reduction in nonfatal cardiac events during a five year follow-up; there were also reductions in psychologic distress, systolic blood pressure, heart rate, and the serum cholesterol concentration.",
"   </p>",
"   <p>",
"    The best data come from the ENRICHD trial, which evaluated 2481 patients post-MI who had either depression or a low level of perceived social support or both [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/85\">",
"     85",
"    </a>",
"    ]. All patients were randomly assigned to six months of usual medical care with or without psychosocial intervention with individual and group cognitive therapy and social support counseling; antidepressant drugs were added for up to 12 months if there was severe depression or no response to cognitive therapy. At a mean follow-up of 29 months, patients receiving psychosocial intervention had less depression and better levels of perceived social support, but there was no reduction in mortality (24 percent in both groups).",
"   </p>",
"   <p>",
"    In the CREATE trial, which evaluated 284 coronary heart disease patients (69 percent post-acute coronary syndrome) with moderate to severe depression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/86\">",
"     86",
"    </a>",
"    ]. Patients were randomly assigned to 20 to 25 minute weekly sessions of clinical management from a trained psychotherapist with or without an additional 45 minutes of interpersonal psychotherapy. No added benefit on depression score was noted with the interpersonal psychotherapy. Two factors that may have contributed to the lack of benefit noted in the CREATE trial were, compared to ENRICHD, a greater degree of underlying depression and a higher level of psychological support in the regular care group. In addition, a cognitive behavioral approach was used in ENRICHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who experience depression after an MI do not receive antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/87\">",
"     87",
"    </a>",
"    ]. This is probably related to several factors, including the high rate of spontaneous remission of depressive symptoms and fears regarding the safety of antidepressants in post-MI patients.",
"   </p>",
"   <p>",
"    Tricyclic antidepressants have many properties that may adversely affect outcomes after MI, including orthostatic hypotension and similarities to class IA antiarrhythmic drugs, which increase arrhythmic deaths and can prolong the QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/67,88\">",
"     67,88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cohort studies have reported conflicting results with regard to the risk of MI in patients taking tricyclic antidepressants, but the results are difficult to interpret since it is not clear if the cardiovascular effects are related to the underlying depression or the treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/32,89\">",
"     32,89",
"    </a>",
"    ]. Furthermore, these studies did not look specifically at post-MI patients.",
"   </p>",
"   <p>",
"    There are more data documenting cardiac safety with selective serotonin uptake inhibitors (SSRIs) post-MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/67\">",
"     67",
"    </a>",
"    ] and, at least one SSRI",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    has been reported to be safe in both a case-control study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/90\">",
"     90",
"    </a>",
"    ] and randomized, controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/91\">",
"     91",
"    </a>",
"    ]. In the SADHART trial (Sertraline Antidepressant Heart Attack Randomized Trial), 369 patients with depression who had been hospitalized for an MI or unstable angina were randomly assigned to 24 weeks of treatment with sertraline (50 to 200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     Sertraline",
"    </a>",
"    was no different from placebo in its effect on any measure of cardiovascular safety including the left ventricular ejection fraction (the primary end point), blood pressure, heart rate, arrhythmias, or QTc prolongation. The incidence of severe cardiovascular adverse events tended to be lower in the sertraline group (14.5 versus 22.4 percent), although this difference was not statistically significant.",
"   </p>",
"   <p>",
"    The findings from SADHART are encouraging, although several limitations of this study should be noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sample size was too small to identify rare adverse events or drug-drug interactions.",
"     </li>",
"     <li>",
"      Antidepressant treatment was not initiated until an average of 34 days following an MI; thus, the safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      in the immediate post-MI period is not clear.",
"     </li>",
"     <li>",
"      Patients who had other medical conditions were excluded from the study, so that the results may not be generalized to the typical population of post-MI patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of SSRIs in the treatment of depression in patients with MI has been evaluated in the SADHART and CREATE trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In SADHART, the depression scale ratings did not improve significantly in the total study population with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      therapy compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/91\">",
"       91",
"      </a>",
"      ]. However, the subset of patients who had a history of major depression prior to their MI did have significant improvements in depressive symptoms with sertraline.",
"     </li>",
"     <li>",
"      In CREATE, which had a 2 x 2 study design to evaluate both psychotherapy (as noted in the preceding section) and drug therapy, 284 patients with moderate to severe depression were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/86\">",
"       86",
"      </a>",
"      ]. After twelve weeks of therapy, the citalopram group had a statistically significant greater decline in a standard measurement of depression compared with placebo. However, the United States Food and Drug Administration issued warnings that citalopram causes dose-dependent QT interval prolongation that can lead to arrhythmias, and thus recommends avoiding citalopram in patients with recent acute myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/92,93\">",
"       92,93",
"      </a>",
"      ]. Additional information about the citalopram warnings and cardiac effects of SSRIs is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link&amp;anchor=H31651631#H31651631\">",
"       \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Cardiac'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither trial was powered to evaluate hard cardiovascular outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;While depression appears to be a risk factor for adverse cardiovascular outcomes and mortality post-MI, the benefits of treating depression are unclear. Both psychotherapy and drug therapy improve depressive symptoms, but may not affect cardiovascular outcomes. On the other hand, several nonrandomized studies have reported a cardiovascular benefit with stress reduction and enhanced social support post-MI.",
"   </p>",
"   <p>",
"    A substantial number of patients who are depressed after an MI will experience spontaneous remission of their symptoms. It is difficult to identify the group that will not experience such a remission, although a history of major depressive episodes before an MI may be a predictor of response to antidepressant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/91\">",
"     91",
"    </a>",
"    ]. If the decision is made to begin antidepressants, the only drug that has demonstrated safety in a randomized trial post-MI is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    , although the limitations of generalizing these results to the general population that are listed above should be noted. Furthermore, it is not clear whether other SSRIs will also prove to be safe; some affect both serotonergic and adrenergic systems, while others are metabolized in different ways and may be subject to different drug interactions.",
"   </p>",
"   <p>",
"    We agree with the 2008 American Heart Association scientific advisory on Depression and Coronary Heart Disease which recommends screening for depressive symptoms in patients with established coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An extensive literature supports a role for mental stress as a trigger of MI and for cardiac events after an MI. However, the clinical utility of this finding remains unclear.",
"   </p>",
"   <p>",
"    A framework to consider for prevention of cardiovascular events at times of increased risk due to known triggers has been designated as Triggered Acute Risk Prevention or TARP [",
"    <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/94\">",
"     94",
"    </a>",
"    ]. Within this framework are five broad approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determination of the absolute cardiovascular risk of a particular individual. Individuals at low risk of having atherosclerotic disease or vulnerable plaques might not require intervention for major emotional stress since their absolute risk of an event attributable to the trigger is low.",
"     </li>",
"     <li>",
"      Modification or avoidance of the specific triggering activity in individuals considered to be at increased absolute risk. Strategies include incorporating relaxation strategies at the time of a severe emotional stress, and providing social support and sensitivity at the time of bereavement. Psychosocial treatment or behavior therapy may prove useful in reducing the adverse consequences of mental stress in triggering cardiovascular events.",
"     </li>",
"     <li>",
"      Long-term preventive approaches directed against the specific trigger. As an example, stress reduction training may limit the frequency and intensity of anger and anxiety.",
"     </li>",
"     <li>",
"      Long-term behavioral and pharmacologic measures directed at traditional risk factors, such as hypertension and hyperlipidemia. This should reduce the likelihood that a trigger would produce an acute cardiovascular event by reducing the atherosclerotic burden, the number of vulnerable plaques, and the vulnerability of individual plaques.",
"     </li>",
"     <li>",
"      Since stressors provoking nonpharmacologic acute emotional stress are frequently unavoidable, benefit may be gained through efforts to interrupt the link between the stressor and the cardiovascular event by pharmacologic means. Although data is limited, preliminary data from the Myocardial Infarction Onset study suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      modifies the relative risk of anger producing MI [",
"      <a class=\"abstract\" href=\"UTD.htm?15/55/16250/abstract/11\">",
"       11",
"      </a>",
"      ]. Beta blockers may also be protective although they do not reduce mental stress-induced blood pressure surges.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of psychotropic drugs and agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and beta blockers may be warranted in selected patient populations, particularly at times of increased stress such as following bereavement, although further study is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=see_link\">",
"       \"Patient information: Heart attack recovery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H187633298\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATION",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The circadian variation in frequency of MI, sudden cardiac death, and myocardial ischemia is characterized by a morning peak. This suggests that cardiac events may be triggered by external activities, particularly those activating the sympathetic nervous system. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Circadian variation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute coronary syndromes have been attributed to acute and chronic emotional distress, stressful life events, and disasters such as earthquakes. In addition, studies have found that personality, depression, anxiety, and anger were risk factors for cardiovascular disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Triggering of acute mi'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      There are several hypothesized mechanisms by which emotional stress might trigger an acute MI. Increases in blood pressure, heart rate, vascular tone, and platelet aggregability may result from mental stress. The onset of an MI may occur when mental stress or anger produces transient pressure surges or vasoconstriction, which disrupts a vulnerable atherosclerotic plaque. If the plaque disruption is large with extensive exposure of collagen and atheromatous core contents to the lumen, this may lead immediately to occlusive thrombosis, with MI or sudden cardiac death. If the disruption is minor, it may lead to nonocclusive thrombosis. In this setting, the patient may be asymptomatic or develop unstable angina or non-ST elevation MI. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major depression develops in almost 20 percent of patients after MI, and is associated with poor compliance with recommendations for post MI therapy. In addition, a case-control study found that patients who suffered an MI and had no history of psychiatric illness were more than three times as likely to commit suicide within one month of the MI, compared with individuals who had no history of MI or psychiatric illness. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Depression and psychosocial stress post MI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spontaneous remission of depressive symptoms occurs in approximately one-half of cases of post-MI depression; the other cases either persist or remit and relapse within one year. Psychosocial interventions for treatment of depressive symptoms have shown little benefit for cardiovascular outcomes. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Psychosocial interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tricyclic antidepressants have many properties that may adversely affect outcomes after MI, including orthostatic hypotension and similarities to class IA antiarrhythmic drugs, which increase arrhythmic deaths and can prolong the QT interval. There are mixed results regarding the efficacy of selective serotonin reuptake inhibitors for treating post-MI depression. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventing cardiovascular events may be possible by determining the cardiovascular risk of a particular individual and modifying specific triggering activities (eg, stress) in individuals considered to be at increased absolute risk, and by using relaxation strategies at the time of a severe emotional stress. In addition, long-term preventive approaches directed against the specific trigger, such as stress reduction training, may limit the frequency and intensity of anger and anxiety. Other long-term preventive approaches and long-term behavioral and pharmacologic measures directed at traditional risk factors, such as hypertension and hyperlipidemia, may help prevent cardiovascular events. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/1\">",
"      DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/2\">",
"      Davies MJ, Thomas AC. Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/3\">",
"      Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/4\">",
"      Cohen MC, Rohtla KM, Lavery CE, et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997; 79:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/5\">",
"      Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol 1994; 23:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/6\">",
"      Aronson D, Weinrauch LA, D'Elia JA, et al. Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy. Am J Cardiol 1999; 84:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/7\">",
"      Sayer JW, Wilkinson P, Ranjadayalan K, et al. Attenuation or absence of circadian and seasonal rhythms of acute myocardial infarction. Heart 1997; 77:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/8\">",
"      Sayer JW, Gutteridge C, Syndercombe-Court D, et al. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 1998; 32:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/9\">",
"      Tofler GH, Stone PH, Maclure M, et al. Analysis of possible triggers of acute myocardial infarction (the MILIS study). Am J Cardiol 1990; 66:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/10\">",
"      Behar S, Halabi M, Reicher-Reiss H, et al. Circadian variation and possible external triggers of onset of myocardial infarction. SPRINT Study Group. Am J Med 1993; 94:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/11\">",
"      Mittleman MA, Maclure M, Sherwood JB, et al. Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators. Circulation 1995; 92:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/12\">",
"      Willich SN, Lewis M, L&ouml;wel H, et al. Physical exertion as a trigger of acute myocardial infarction. Triggers and Mechanisms of Myocardial Infarction Study Group. N Engl J Med 1993; 329:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/13\">",
"      Myers A, Dewar HA. Circumstances attending 100 sudden deaths from coronary artery disease with coroner's necropsies. Br Heart J 1975; 37:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/14\">",
"      Parkes CM, Benjamin B, Fitzgerald RG. Broken heart: a statistical study of increased mortality among widowers. Br Med J 1969; 1:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/15\">",
"      Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/16\">",
"      Trichopoulos D, Katsouyanni K, Zavitsanos X, et al. Psychological stress and fatal heart attack: the Athens (1981) earthquake natural experiment. Lancet 1983; 1:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/17\">",
"      Leor J, Poole WK, Kloner RA. Sudden cardiac death triggered by an earthquake. N Engl J Med 1996; 334:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/18\">",
"      Brown DL. Disparate effects of the 1989 Loma Prieta and 1994 Northridge earthquakes on hospital admissions for acute myocardial infarction: importance of superimposition of triggers. Am Heart J 1999; 137:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/19\">",
"      Glass RI, Zack MM Jr. Increase in deaths from ischaemic heart-disease after blizzards. Lancet 1979; 1:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/20\">",
"      Kario K, Matsuo T, Kobayashi H, et al. Earthquake-induced potentiation of acute risk factors in hypertensive elderly patients: possible triggering of cardiovascular events after a major earthquake. J Am Coll Cardiol 1997; 29:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/21\">",
"      Meisel SR, Kutz I, Dayan KI, et al. Effect of Iraqi missile war on incidence of acute myocardial infarction and sudden death in Israeli civilians. Lancet 1991; 338:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/22\">",
"      Allegra JR, Mostashari F, Rothman J, et al. Cardiac events in New Jersey after the September 11, 2001, terrorist attack. J Urban Health 2005; 82:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/23\">",
"      Ohlin B, Nilsson PM, Nilsson JA, Berglund G. Chronic psychosocial stress predicts long-term cardiovascular morbidity and mortality in middle-aged men. Eur Heart J 2004; 25:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/24\">",
"      Pignalberi C, Patti G, Chimenti C, et al. Role of different determinants of psychological distress in acute coronary syndromes. J Am Coll Cardiol 1998; 32:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/25\">",
"      Shekelle RB, Gale M, Ostfeld AM, Paul O. Hostility, risk of coronary heart disease, and mortality. Psychosom Med 1983; 45:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/26\">",
"      Kawachi I, Colditz GA, Ascherio A, et al. Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation 1994; 89:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/27\">",
"      Shen BJ, Avivi YE, Todaro JF, et al. Anxiety characteristics independently and prospectively predict myocardial infarction in men the unique contribution of anxiety among psychologic factors. J Am Coll Cardiol 2008; 51:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/28\">",
"      Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008; 118:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/29\">",
"      Wassertheil-Smoller S, Shumaker S, Ockene J, et al. Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med 2004; 164:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/30\">",
"      Bruce ML, Leaf PJ. Psychiatric disorders and 15-month mortality in a community sample of older adults. Am J Public Health 1989; 79:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/31\">",
"      Anda R, Williamson D, Jones D, et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology 1993; 4:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/32\">",
"      Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996; 94:3123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/33\">",
"      Ariyo AA, Haan M, Tangen CM, et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 2000; 102:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/34\">",
"      Fredman L, Schoenbach VJ, Kaplan BH, et al. The association between depressive symptoms and mortality among older participants in the Epidemiologic Catchment Area-Piedmont Health Survey. J Gerontol 1989; 44:S149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/35\">",
"      Whooley MA, de Jonge P, Vittinghoff E, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008; 300:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/36\">",
"      Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 1994; 154:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/37\">",
"      Penninx BW, Guralnik JM, Mendes de Leon CF, et al. Cardiovascular events and mortality in newly and chronically depressed persons &gt; 70 years of age. Am J Cardiol 1998; 81:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/38\">",
"      Kawachi I, Sparrow D, Spiro A 3rd, et al. A prospective study of anger and coronary heart disease. The Normative Aging Study. Circulation 1996; 94:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/39\">",
"      Williams JE, Paton CC, Siegler IC, et al. Anger proneness predicts coronary heart disease risk: prospective analysis from the atherosclerosis risk in communities (ARIC) study. Circulation 2000; 101:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/40\">",
"      Chang PP, Ford DE, Meoni LA, et al. Anger in young men and subsequent premature cardiovascular disease: the precursors study. Arch Intern Med 2002; 162:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/41\">",
"      M&ouml;ller J, Hallqvist J, Diderichsen F, et al. Do episodes of anger trigger myocardial infarction? A case-crossover analysis in the Stockholm Heart Epidemiology Program (SHEEP). Psychosom Med 1999; 61:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/42\">",
"      Spencer FA, Goldberg RJ, Becker RC, Gore JM. Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J Am Coll Cardiol 1998; 31:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/43\">",
"      Cold exposure and winter mortality from ischaemic heart disease, cerebrovascular disease, respiratory disease, and all causes in warm and cold regions of Europe. The Eurowinter Group. Lancet 1997; 349:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/44\">",
"      Sheth T, Nair C, Muller J, Yusuf S. Increased winter mortality from acute myocardial infarction and stroke: the effect of age. J Am Coll Cardiol 1999; 33:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/45\">",
"      Hollander JE, Hoffman RS. Cocaine-induced myocardial infarction: an analysis and review of the literature. J Emerg Med 1992; 10:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/46\">",
"      Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/47\">",
"      Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation 2001; 103:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/48\">",
"      Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation 2001; 103:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/49\">",
"      Magari SR, Hauser R, Schwartz J, et al. Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation 2001; 104:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/50\">",
"      Suwa T, Hogg JC, Quinlan KB, et al. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 2002; 39:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/51\">",
"      Brook RD, Franklin B, Cascio W, et al. Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation 2004; 109:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/52\">",
"      Peters A, Dockery DW, Muller JE, Mittleman MA. Increased particulate air pollution and the triggering of myocardial infarction. Circulation 2001; 103:2810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/53\">",
"      Peters A, von Klot S, Heier M, et al. Exposure to traffic and the onset of myocardial infarction. N Engl J Med 2004; 351:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/54\">",
"      Lipovetsky, N, Hod, H, Roth, A, et al. Heavy meals as a trigger for a first event of the acute coronary syndrome: A case-crossover study. IMAJ 2004; 6:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/55\">",
"      Gnecchi-Ruscone T, Piccaluga E, Guzzetti S, et al. Morning and Monday: critical periods for the onset of acute myocardial infarction. The GISSI 2 Study experience. Eur Heart J 1994; 15:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/56\">",
"      Kelly-Hayes M, Wolf PA, Kase CS, et al. Temporal patterns of stroke onset. The Framingham Study. Stroke 1995; 26:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/57\">",
"      Phillips DP, Jarvinen JR, Abramson IS, Phillips RR. Cardiac mortality is higher around Christmas and New Year's than at any other time: the holidays as a risk factor for death. Circulation 2004; 110:3781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/58\">",
"      Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/59\">",
"      Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/60\">",
"      Yeung AC, Vekshtein VI, Krantz DS, et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med 1991; 325:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/61\">",
"      Verrier RL, Hagestad EL, Lown B. Delayed myocardial ischemia induced by anger. Circulation 1987; 75:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/62\">",
"      Rozanski A, Bairey CN, Krantz DS, et al. Mental stress and the induction of silent myocardial ischemia in patients with coronary artery disease. N Engl J Med 1988; 318:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/63\">",
"      Falk E. Why do plaques rupture? Circulation 1992; 86:III30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/64\">",
"      WOLF S, McCABE WR, YAMAMOTO J, et al. Changes inserum lipids in relation to emotional stress during rigid control of diet and exercise. Circulation 1962; 26:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/65\">",
"      Adams DO. Molecular biology of macrophage activation: a pathway whereby psychosocial factors can potentially affect health. Psychosom Med 1994; 56:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/66\">",
"      Ziegelstein RC. Depression in patients recovering from a myocardial infarction. JAMA 2001; 286:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/67\">",
"      Jiang W, Davidson JR. Antidepressant therapy in patients with ischemic heart disease. Am Heart J 2005; 150:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/68\">",
"      Ruberman W, Weinblatt E, Goldberg JD, Chaudhary BS. Psychosocial influences on mortality after myocardial infarction. N Engl J Med 1984; 311:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/69\">",
"      Orth-Gom&eacute;r K, Wamala SP, Horsten M, et al. Marital stress worsens prognosis in women with coronary heart disease: The Stockholm Female Coronary Risk Study. JAMA 2000; 284:3008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/70\">",
"      Bush DE, Ziegelstein RC, Tayback M, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001; 88:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/71\">",
"      Lesp&eacute;rance F, Frasure-Smith N, Talajic M, Bourassa MG. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002; 105:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/72\">",
"      Beck CA, Joseph L, B&eacute;lisle P, et al. Predictors of quality of life 6 months and 1 year after acute myocardial infarction. Am Heart J 2001; 142:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/73\">",
"      Frasure-Smith N, Lesp&eacute;rance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993; 270:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/74\">",
"      Frasure-Smith N, Lesp&eacute;rance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/75\">",
"      Carinci F, Nicolucci A, Ciampi A, et al. Role of interactions between psychological and clinical factors in determining 6-month mortality among patients with acute myocardial infarction. Application of recursive partitioning techniques to the GISSI-2 database. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. Eur Heart J 1997; 18:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/76\">",
"      Frasure-Smith N, Lesp&eacute;rance F, Gravel G, et al. Social support, depression, and mortality during the first year after myocardial infarction. Circulation 2000; 101:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/77\">",
"      Larsen KK, Agerbo E, Christensen B, et al. Myocardial infarction and risk of suicide: a population-based case-control study. Circulation 2010; 122:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/78\">",
"      Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/79\">",
"      Travella JI, Forrester AW, Schultz SK, Robinson RG. Depression following myocardial infarction: a one year longitudinal study. Int J Psychiatry Med 1994; 24:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/80\">",
"      Hance M, Carney RM, Freedland KE, Skala J. Depression in patients with coronary heart disease. A 12-month follow-up. Gen Hosp Psychiatry 1996; 18:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/81\">",
"      Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med 1996; 58:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/82\">",
"      Frasure-Smith N. In-hospital symptoms of psychological stress as predictors of long-term outcome after acute myocardial infarction in men. Am J Cardiol 1991; 67:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/83\">",
"      Denollet J, Brutsaert DL. Reducing emotional distress improves prognosis in coronary heart disease: 9-year mortality in a clinical trial of rehabilitation. Circulation 2001; 104:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/84\">",
"      Friedman M, Breall WS, Goodwin ML, et al. Effect of type A behavioral counseling on frequency of episodes of silent myocardial ischemia in coronary patients. Am Heart J 1996; 132:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/85\">",
"      Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; 289:3106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/86\">",
"      Lesp&eacute;rance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/87\">",
"      Ziegelstein RC. Depression after myocardial infarction. Cardiol Rev 2001; 9:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/88\">",
"      Roose SP. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J 2000; 140:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/89\">",
"      Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000; 108:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/90\">",
"      Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/91\">",
"      Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288:701.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). file://www.fda.gov/Drugs/DrugSafety/ucm269086.htm (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses file://www.fda.gov/Drugs/DrugSafety/ucm297391.htm (Accessed on March 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/55/16250/abstract/94\">",
"      Tofler GH, Muller JE. Triggering of acute cardiovascular disease and potential preventive strategies. Circulation 2006; 114:1863.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4854 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16250=[""].join("\n");
var outline_f15_55_16250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CIRCADIAN VARIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRIGGERING OF ACUTE MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Life events and other crises",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Personality and mood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Anxiety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Anger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Seasonal pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other social factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Myocardial ischemia and plaque rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Altered platelet activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Altered cardiovascular risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DEPRESSION AND PSYCHOSOCIAL STRESS POST MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Psychosocial interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H187633298\">",
"      SUMMARY AND RECOMMENDATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/4854\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/4854|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?39/7/40051\" title=\"algorithm 1\">",
"      Stress and coronary thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/4854|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/35/7743\" title=\"figure 1A\">",
"      Circadian pattern AMI SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/37/29278\" title=\"figure 1B\">",
"      Circadian pattern UAP nonQ MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/57/30621\" title=\"figure 2\">",
"      Depression cardiovasc events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/18/302\" title=\"figure 3\">",
"      Seasonal pattern MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/33/41501\" title=\"figure 4\">",
"      Depression mortality after MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=related_link\">",
"      Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=related_link\">",
"      Diabetic autonomic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=related_link\">",
"      Fibrinolytic markers and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=related_link\">",
"      Heart rate variability: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10601?source=related_link\">",
"      Heart rate variability: Use after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=related_link\">",
"      Patient information: Heart attack recovery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42135?source=related_link\">",
"      Silent myocardial ischemia: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_55_16251="Types of germ cell neoplasms";
var content_f15_55_16251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of ovarian germ cell neoplasms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Dysgerminoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endodermal sinus tumor (yolk sac tumor)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Embryonal carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Polyembryoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Choriocarcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Teratoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Immature (solid, cystic, both)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mature",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Solid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Cystic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Mature cystic teratoma (dermoid cyst)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Mature cystic teratoma (dermoid cyst) with malignant transformation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Monodermal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Struma ovarii",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Carcinoid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Struma ovarii and carcinoid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mixed forms",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16251=[""].join("\n");
var outline_f15_55_16251=null;
var title_f15_55_16252="Prog fac CTLS AML";
var content_f15_55_16252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognostic factors for CTLS in AML in the training sample: multivariate analysis and risk scores",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Co-variate",
"      </td>",
"      <td class=\"subtitle1\">",
"       Unfavorable categories",
"      </td>",
"      <td class=\"subtitle1\">",
"       Regression coefficient",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        CTLS",
"       </p>",
"       <p>",
"        Odds ratio (95% CI)",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       p value",
"      </td>",
"      <td class=\"subtitle1\">",
"       Score",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       WBC",
"      </td>",
"      <td>",
"       &le;25 x 10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </td>",
"      <td rowspan=\"3\">",
"       1.1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td rowspan=\"3\">",
"       &lt;0.001",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       25-75 x 10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </td>",
"      <td>",
"       2.7 (1.4-5.4)",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;75 x 10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </td>",
"      <td>",
"       7.3 (2.0-29.1)",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Uric acid",
"      </td>",
"      <td>",
"       &le;7.5 mg/dL",
"      </td>",
"      <td rowspan=\"2\">",
"       2.2",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td rowspan=\"2\">",
"       &lt;0.001",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;7.5 mg/dL",
"      </td>",
"      <td>",
"       9.1 (3.3-26.6)",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       LDH",
"      </td>",
"      <td>",
"       &le;1 x ULN",
"      </td>",
"      <td rowspan=\"3\">",
"       1.2",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td rowspan=\"3\">",
"       0.005",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1-4 x ULN",
"      </td>",
"      <td>",
"       3.9 (1.5-10.8)",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;4 x ULN",
"      </td>",
"      <td>",
"       15.2 (2.2-96.8)",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LTLS: laboratory tumor lysis syndrome; CTLS: clinical tumor lysis syndrome; WBC: white blood cell count; ULN: upper limit of normal.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Montesinos P, Lorenzo I, Martin G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008; 93:9. Copyright &copy;2008 Ferrata-Storti Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16252=[""].join("\n");
var outline_f15_55_16252=null;
var title_f15_55_16253="Myocardial action potential";
var content_f15_55_16253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Myocardial action potential",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 245px; background-image: url(data:image/gif;base64,R0lGODlh1AH1ANUAAP///wCK3wAAAICAgIDF78DAwEBAQABFb/Dw8BAQEDAwMCAgIODg4LCwsKCgoHBwcNDQ0FBQUJCQkGBgYABemQARGwAIDQBWiwB4wwAiNwAzUwArRQBnpwCB0QBwtQBNfQAZKYCit0CFr8Di9wA8YWCTsyAxO0BidwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADUAfUAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqgwwOAxIMQw2vsau2t7hPDgVEBgK/CQgADwIKCQm1ucrLuQYDRA0ICAoCBQgCCQASAg/M3t+ozkUMAwkGAAUC5+nn4O7vm+m/80MQBuYI7OjqQgUD/wADCvzHC57Bg33yFVAwoUDBIQMEDIBQDEADARH6DRxgwNnGhwhDiqwjbsiCB+UEOACwQECDCCqV/BtJsyaeByuHwMT2DAAE/2oJusnsabOoUUUzISl0YkBoHQcGIByBKvWoVTBJHxFziSRdzwE5v/B74ktjMiIRQV5dmyWro5YCJgwpMMHABAgT1D0DK0SCgQgNhLh6GaGqEHINHhgI7LPuA2EOBCwYEAuqAQkAECt+VqDlAIeUAVgGDCAt29NtiTa6KCGBAGHpFHAcQG3BOX7EHsAM7GtBbSLpJlODwCCBbOPDsEXNDVOCvHsqHbg24KoagAgoW5Kzjro7FbeM8jLIuxJmLQZehfBDfi1jWQDUgEu0KHFbYGJSxyaYHNFA+ovPvGcaOQa05A933iX4BHiKXKNOSwoA8F4/8wHAz1j8vDfhPpxJZP+aaRjyB1Z66QlYTXEKOJDXgWop6CISDCayzQT/uAbBjP58hlFg/OwWEWYaCiBfQ8NRFEFn2Vi4QAEMwPSZKyTO50sDEKSVzpG+sPjilknEiAg1wiTXzQAtJcAbNhaegwBMQQkRpHxl5uQAhFVFJAAECEzgWgI6dvhMA65JYFpexlVjGpeIoqUaM+kl6ugbXuLS6KOUqhFppZhWemmmnCK6aaegKvhpqKSeNuohv4RZ6qp4nGrILwqoyuqscrhayDwR0qorHLYS8ktLYe0qbBq9DvJLZAsMqywaxQryC0sxLSutGM0G8iyyThRg2LTcMlEtIM9CG+wRVY7V7bldLvr/SLjYKuGLuejGqyglrjEG7BL6yKuvEN/+kZdcokkmqxH57itvv35clCS0GSVRsMHoIuxHuD79ghm52yhgDcQRq7uukENsc+cR7/7SIsfKStwHxULAtMDAKBusMh8sA4BASw3HzPHMe9RcsQAX6yyzx474rM0v2wodL896GH2dwErry3QeTk9TDMxRSzs1Hk7bTE2sWZ+79R1de3112J0i4IoDWBcxth1lmw022phS40uuQ1USt9xt0+3iRRnttsTbdext9pJ+OxrRXhVqJFBHGxG0iOFmc9N34qbOtzhwA0Ee+cm+gtwEAlshjrmL23RDTNAwEt0I5XPB9ZgYDAgq/8Hlp3PCgGSdCXDWEYTTAfsQpP86Lhcl4537KHNKdrwRwc8xPHBwLfA8FtHcjODyzEQvx/RFNO88GNpx/433cYBvhPjWd5G6+ee7zoj6U8GVwATRYEEMwPB3L//kosuC+H4RAVhQwWWS658y0AcH+ikBAg+gBq4ekDQmzOMX/1NgKRj4BgcyoXY7mYddPvM7DSKEg27woBMQ0AA9XVCENGKSCQ2CwjaoMAroGUBdXggMZzSghDO8RQ3ZcEMr5HCHLzTHAH4YRCFmMBFF3AIDZgGdFyqgKUvcWBNHMcQ1RPELU+SIa3iIjQJWcIuZ6KIavjiGfMxCMRKcx/0Yg8Y0Pv8REWxUw40iMMaz1fESakxDHtvQQtfM7Y+UCCQaBukGqx0SkZFQ5BkY2civ4Q6Sh5CkGShZST9i0hGaLAMnO/nITyLljqgKICO0h0pT+iGUZBjlGyKDDFcuApZjkOUbfME/W2aylbdSZSPkATpfAgKXYtDlG/LSDmMWAplhUKYbihMtZw4CmmCQphsi8jJrXhOYoaMEK71pBJRAYD+XtBQ4jSXMR1zEd+QkQgIcwMc21QGbYmnnI3zRzHhWYwER4Igd8OkFbb5hd1yJJ0ucpJiBrtNZ+nwENxV6NGScxKF6i6gjEFAvihInH+kk1kOtpVFH/EuhJdENRilhUDgojJz/5LDNP6640km0tIElhaQ8LjjSMBC0CzftYE4RmQ+GOOSMWWgFLWSx1LyxdKjzgypFrVCyYCTHGLVMV0YzEVSOdeSrHXEKF7JHDWug6X1afWomOmpNMvaTC+Qwxz7WYa4cBcRzHwFgJk461Szs1GRCsAc+9FEwuwIErwMpJkQz8dJ4+oU0V1CIQ7TIL4lQJEKAc6pNpboI1wDRlVv5BR25cJKUrKQlL6km8HpqB7WBRVZddcOUyDmfNb1VCzvhU2CBItbVMsJuFRlCbNuwOW8mtKH3ZC0dMis49XBWERe5rS1hYgBqsK5Wyp3D5oqLUE3sbmHOXBM2eovdW2quQg+7/4RnvRlS4mZXDu9bXWV7eYnZWrO6bGvVe+OwuyWVDwB52e8xG2fM0DakpoloXvvctL1LRJecLOQngiHxi89O4rvehCBc6BuHn25huG9YrzN7Q8E7eFgLIJZtQo0pgdFO+GOdKG5ftStgrj2XEQ/2ZTVKBq/ybrYTGPblcsBKXl7VmGw3juqM6XDiLKTYDS1B6h83cr1tHhluSV5Eloxwo9du0a0vLlqWFbHlIlxQuv2brJql7F61doIY6lpJd5uo5smymQ1NxsKTiUvgucD5yzxEs5XdzImIFBkq3NgilcP8ujEnIr29aPCSfXrlwjkaEeldyAC2YmHuDfmrRYZUpf+Fd+lDUCRZRGCABBfgYg3u+MyMVrIn9rzkPF+B1kSEpyvRU+c7r8HWVsD1GuxrSjvBOrmE5sSfXWmnK4Y11nr1xDZy9kkEkOl+vsbzqKVX6kMEx5ki02+yOSHsYTWgN9elsRbqbGlQGIjZv/AIX5Dt5Au2+xPNgfcLBd3mek/23p4w9K7rrC1oQwGD8+Y2KHI86X7rWYQAB3K5TTiL0FikqWl9OBGg8r1u41HXDaeCIzV21WN0emYID5BEOr1Jjx+izCGfQl6Cdo1soLV1KLa3LyyeQpcbIsAxp8J0ioEefhS2c/JOrBUi0vFQRITDQS/CX61jsn8Rtq5Ij9xnlv7/mvZG0+eFgHTUiSBZhwjDNXO9LH2oDb1KF8A1im15KOY89icEGOiohUmVS7PtpoeiwnV/gngT7RPeDq7v6QN7IWAeeGohHqeiAHrjx4Awwyod8k6Py+QpfwICeP7zoA+96D0vggOY/gAZyMDpDyCC0bv+9bCPPeh/Ifva2/72uM997EsgABPo/vfAB/4IzDeAAwTg+MhPvvKXz3zTM//50I++9KH/i+lb//rYz772pY+B6m//++D/PgGIb/zwL9/55k//872v/va73/wWEAAF3k//8I+fe8WnP/rrn3728///AIh8GiAAGhCABgh997c8+fd++3eA2Nd9FuCAEuh+/xQgABE4gRKYgLmzgO7XgBgYfRWYAR84gt8Xf/NHggCogafDge3ngSiofAcgAOX3gjQIfQNYgDVIfyqIOSyofi6Ygxkgfzk4hMpXgRdIhOq3g4nTg+n3gzUYfxiAhFIIhVKYfkroN0xofk5Ig/5XhTUYhCfoheJHfvo3g0jYhWKIgjFohmmIfVdIN1kYflv4gmjYhh8YgnaofW+INnEIfnOIgnWYhxIIgYLohmTIgGw4hIFYiAdYAQJwAYw4fXsYNn34fX84ghcgABUQiZioiZwYfZOYNZW4fZf4gY4IiZ+IgaeYiswXilEzitpXihOYiZvIirPoibaYfK6oNLCYff+yKIGrmIvA+IjCeHy7KDS9iH2/eIBGWIwSSIvOeIw6k4zXt4wGeIPOOIxhaIvSGDPUaH3WCIAdYILZ6IAxuAHF2I0o843TF47/twG4WI4G2H0CEIW5qI47k4haqI8j+AG/4AHy6IDwyI/q5wEcYI8peIgdSJAT6AG/8AEB6YBGCJD15wHxx5BJqJAtiJEHeAHxh44R6YAg8JD1N5IyaID4CDHsKH3u2H4X4IgCAAIdEJIO2AHwKAAbMJMtaAEkcJIBmJIyw5G+KJT0RwEaEH+aiIo0KYH+qIkHgJDg55AUsIYoqZE+SJTqZ5RImZRLOYIeAJM4uY2x+EJYuX1AuS//Kxl9LSl9HcABF3AAGxCE82ABGiCWXYmBFHCTTgmV14cBHMABN8iXOqgvs5BfQjALBiQTZdmOi/l8fnkAGiCXPESXdnmXJIgBBwCWG1CZ7eiTCRkvefE1QkAMWHVyjamWQklGqnlBGbABB3ABHKCTlimFecmargmbslmDZ8kpakceNXc0ocYvpwl9pbiarKkBB3CQs8mImAmWxvmc0KmakhgvsVEaEnF17WB5/2AAqrd6p8cB18cBq5d63gmey3mex9eWbxmX0dmezzmdyjJ1vAAhnoGdjvM4SRcQIWB7IaB1/7CfwRegAjqgBFqgBnqgCOp5w6csZbcxtSMBMKEt/xWRWRm3eYnTAAeSK3mnWm3nV2pmocLiC/cTJj8xXodXb/QAoryYXSbjECq6ovX2D3v3okvDohBHo95oozgKow8HEKLhAA5wO7PgdTtKKirzQhKiDsqBEUXaLWPTERJyDlDapNPypFJ6pVRapVcGpVzKb1m6KsD2pVwSpmL6ImRapqLyeGiaMmq6psJypm6KGnAap2wxp3R6FXZ6p0eRp3paFHzapzXxp4A6EoI6qCFRqIZ6EIiaqPCwqIzqDo76qPEjqXzYppSqKZZ6qY8SqZqaC5zaqU4EqsiYqaK6JZ9aqsNkGK7Fc4jJcqeKqolQLs1kbLVEmianWbD6KO/STHUy5CS/eXO+lauVAmnkYZ/osBGIFRBxJ6wIIZ8U8lZqZ6za6Z9bx6xH0aBh8jDSATZqR6HWSio3Ugwbsw1BwRcbOqPf6ig8xgs8dg4lak/pGq/yOq/0Wq/2eq/4mq/6uq/82q/++q8AG7ACO7AEW7AGe7DeEQQAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Representation of an action potential in ventricular myocardial cells. An action potential is generated when the membrane potential is partially depolarized from the resting level (Em) to the threshold potential (Et). The ensuing rapid phase 0 depolarization is mediated by sodium entry into the cells due to a marked increase in the number of open sodium channels in the cell membrane. Repolarization in phases 1 and 3 results from potassium exit from the cells as the sodium channels are closed and potassium channels opened. The phase 2 plateau reflects the slow entry of calcium into the cells, which counteracts the effect of potassium exit. Sodium leaves and potassium reenters the cells during phase 4 recovery via the Na-K-ATPase pump.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16253=[""].join("\n");
var outline_f15_55_16253=null;
var title_f15_55_16254="Diabetes endpoints and control";
var content_f15_55_16254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Efficacy of intensive glycemic control in type 2 diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 301px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier plots of any diabetes-related endpoint in patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study who were randomly assigned to either intensive therapy with a sulfonylurea or insulin or to conventional treatment with diet; drugs were added if there were hyperglycemic symptoms or if the fasting blood glucose concentration was greater than 270 mg/dL (15 mmol/L). Intensive therapy was associated with a 12 percent reduction in the development of any diabetes-related endpoint (P = 0.03); it was estimated that 19.6 patients would have to be treated to prevent any single endpoint in one patient at 10 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998; 352:837.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16254=[""].join("\n");
var outline_f15_55_16254=null;
var title_f15_55_16255="Oblique metacarpal shaft fracture";
var content_f15_55_16255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oblique metacarpal shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This oblique view shows&nbsp;a mid-shaft fracture of the 5th metacarpal with apex dorsal angulation. The&nbsp;degree of angulation is determined&nbsp;by the&nbsp;lateral view (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Josh Bloom, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_55_16255=[""].join("\n");
var outline_f15_55_16255=null;
